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ABSTRACT	  	  The	  general	  aim	  of	  this	  thesis	  was	  to	  study	  temporomandibular	  joint	  (TMJ)	  pain	  and	  bone	  tissue	  destruction	  in	  patients	  with	  rheumatoid	  arthritis	  (RA),	  in	  particular:	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines,	  systemic	  inflammatory	  activity,	  and	  the	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  and	  quality	  of	  life.	  This	  thesis	  comprises	  three	  parts.	  The	  aim	  of	  the	  first	  part	  was	  to	  investigate	  the	  impact	  of	  TMJ	  pain	  and	  inflammation	  on	  daily	  activities	  and	  quality	  of	  life	  in	  relation	  to	  systemic	  inflammatory	  activity.	  The	  aim	  of	  the	  second	  part	  was	  to	  investigate	  how	  local	  and	  systemic	  cytokine	  levels	  of	  tumor	  necrosis	  factor	  (TNF)	  and	  interleukin	  1	  (IL-­‐1)	  interact	  to	  modulate	  TMJ	  pain	  in	  RA.	  And	  the	  aim	  of	  the	  third	  study	  was	  to	  investigate	  the	  relationship	  between	  inflammatory	  mediators	  in	  TMJ	  synovial	  fluid	  and	  blood	  versus	  bone	  tissue	  destruction	  by	  magnetic	  resonance	  imaging	  (MRI)	  of	  the	  TMJ.	  	  Each	  study	  in	  this	  thesis	  examined	  subjects	  from	  the	  same	  group	  of	  patients	  with	  a	  recent	  RA	  diagnosis.	  In	  the	  first	  study,	  33	  patients	  participated;	  in	  the	  second,	  26;	  and	  in	  the	  third,	  22.	  Each	  study	  performed	  similar	  clinical	  examinations.	  The	  patients	  rated	  their	  TMJ	  pain	  (resting,	  movement,	  loading	  and	  on	  palpation)	  on	  a	  scale	  from	  0	  to	  10	  and	  underwent	  MRI	  examination	  to	  assess	  signs	  of	  TMJ	  erosions.	  We	  obtained	  and	  	  analyzed	  TMJ	  synovial	  fluid	  samples	  for	  TNF,	  IL-­‐1ra,	  anti-­‐citrullinated	  protein	  antibodies	  (ACPA),	  and	  rheumatoid	  factor	  (RF)	  and	  blood	  samples	  for	  erythrocyte	  sedimentation	  rate	  (ESR),	  C-­‐reactive	  protein	  (CRP),	  ACPA	  and	  RF.	  Studies	  I	  and	  II	  used	  non-­‐parametric	  statistics	  (Mann-­‐Whitney	  U-­‐test,	  Spearman	  correlation)	  while	  Study	  III	  used	  parametric	  statistics	  (student’s	  t-­‐test	  and	  Pearson	  correlation).	  A	  probability	  level	  of	  less	  than	  0.05	  was	  considered	  as	  significant.	  	  The	  first	  study	  found	  that	  TMJ	  pain	  intensity,	  together	  with	  systemic	  inflammatory	  activities,	  plays	  an	  important	  role	  in	  the	  impact	  of	  TMJ	  pain	  on	  daily	  living	  and	  quality	  of	  life	  in	  RA.	  The	  second	  study	  found	  that	  a	  high	  TNF	  to	  TNFsRII	  ratio	  in	  the	  synovial	  fluid	  of	  the	  TMJ	  was	  associated	  with	  TMJ	  pain	  on	  palpation	  in	  patients	  with	  RA.	  High	  levels	  of	  TNF	  were	  found	  
 vi 
to	  be	  associated	  with	  high	  levels	  of	  TNFsRII;	  however,	  increases	  in	  local	  cytokine	  control	  in	  the	  presence	  of	  elevated	  levels	  of	  TNF	  was	  likely	  insufficient	  to	  control	  or	  inhibit	  the	  inflammatory	  process.	  Presence	  of	  ACPA	  in	  TMJ	  synovial	  fluid	  was	  associated	  with	  elevated	  TNF	  levels	  but	  not	  with	  TNFsRII	  levels.	  	  The	  third	  study	  found	  that	  TNF	  in	  TMJ	  synovial	  fluid	  modulates	  TMJ	  bone	  tissue	  resorption	  in	  patients	  with	  RA.	  However,	  bone	  tissue	  destruction	  was	  associated	  with	  a	  low	  degree	  of	  endogenous	  cytokine	  control.	  In	  conclusion,	  TNF,	  including	  its	  endogenous	  control	  system,	  seems	  to	  be	  involved	  in	  TMJ	  inflammation,	  which	  results	  in	  TMJ	  pain	  and	  tissue	  destruction.	  In	  turn,	  TMJ	  pain	  has	  a	  negative	  impact	  on	  daily	  living	  and	  quality	  of	  life	  in	  patients	  with	  RA.	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DEFINITIONS	  	  
Local	  inflammation	   Inflammatory	  mechanisms	  with	  local	  effects	  at	  the	  
inflammatory	  site	  
Systemic	  inflammation	   Inflammatory	  mechanisms	  with	  peripheral	  and/or	  central	  
effects	  mediated	  by	  factors	  present	  in	  the	  circulatory	  system	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INTRODUCTION	  	  
Rheumatoid	  arthritis	  Rheumatoid	  arthritis	  (RA)	  is	  a	  chronic,	  progressive,	  systemic,	  and	  inflammatory	  autoimmune	  disease.	  It	  develops	  in	  a	  genetically	  susceptible	  host	  for	  whom	  environmental	  factors	  like	  smoking	  can	  contribute	  to	  its	  initiation	  and	  development	  (1).	  RA	  has	  a	  world-­‐wide	  prevalence	  of	  0.5-­‐1.0%	  (2-­‐4)	  and	  is	  about	  three	  times	  more	  common	  in	  females	  than	  in	  males	  (5).	  	  
CLINICAL  PRESENTATION  RA	  primarily	  involves	  the	  musculoskeletal	  system,	  often	  in	  a	  bilateral	  manner,	  in	  which	  the	  most	  commonly	  affected	  joints	  are	  the	  metacarpophalangeal	  joints,	  wrists,	  proximal	  interphalangeal	  joints,	  metatarsophalangeal	  joints,	  shoulders,	  knees,	  ankles,	  and	  elbows.	  RA	  is	  characterized	  by	  abnormal	  immune	  system	  reactions	  that	  result	  in	  synovial	  inflammation	  with	  pain,	  synovial	  hyperplasia,	  autoantibody	  production	  (such	  as	  anti–citrullinated	  protein	  antibodies	  [ACPA]	  and	  rheumatoid	  factor	  [RF]),	  and	  cartilage	  and	  bone	  tissue	  destruction.	  RA	  not	  only	  affects	  the	  musculoskeletal	  system	  but	  can	  also	  cause	  cardiovascular,	  pulmonary,	  psychological,	  and	  skeletal	  diseases	  (1).	  	  Clinically,	  the	  most	  characteristic,	  but	  far	  from	  only	  symptom	  of	  RA	  is	  joint	  and	  muscle	  pain.	  Patients	  with	  RA	  also	  present	  with	  fatigue;	  stiffness	  in	  the	  joints	  and	  muscles,	  especially	  in	  the	  early	  morning	  or	  after	  being	  ill	  for	  a	  period	  of	  time;	  low-­‐grade	  fever;	  and	  muscle	  weakness.	  These	  patients	  may	  also	  develop	  joint	  deformity	  over	  time,	  due	  to	  cartilage	  and	  bone	  tissue	  destruction,	  and	  rheumatoid	  nodules	  in	  the	  skin	  triggered	  by	  the	  inflammatory	  process	  (6).	  	  
CLINICAL  COURSE    RA	  often	  begins	  bilaterally	  in	  small,	  peripheral	  joints	  with	  larger	  joints	  becoming	  involved	  over	  time.	  The	  disease	  course	  can	  range	  from	  brief	  and	  self-­‐limiting	  to	  prolonged	  and	  progressive	  (7).	  Also,	  the	  severity	  of	  the	  
 2 
disease	  may	  vary	  from	  mild	  to	  severe.	  The	  most	  common	  pattern	  of	  onset	  is	  gradual	  with	  a	  polycyclic	  progression	  (7)	  (Fig.	  1).	  
Figure	  1.	  Patterns	  of	  the	  clinical	  articular	  course	  of	  rheumatoid	  arthritis	  over	  five	  
years	  in	  adult	  patients	  with	  early-­‐diagnosed	  rheumatoid	  arthritis.	  The	  figure	  shows	  
three	  major	  patterns	  of	  the	  articular	  course	  of	  rheumatoid	  arthritis	  based	  on	  clinical	  
findings.	  (Reprinted	  with	  permission	  from	  Mosby	  Elsevier)	  There	  is	  currently	  no	  definite	  consensus	  regarding	  the	  prognostic	  factors	  for	  RA.	  Research	  has	  shown	  that	  radiographic	  damage	  at	  the	  beginning	  of	  the	  disease	  is	  an	  important	  predictor	  of	  clinical	  outcomes	  and	  radiographic	  progression	  (8).	  In	  the	  first	  years	  after	  symptom	  onset,	  joint	  destruction	  often	  begins	  very	  early	  and	  progresses	  rapidly.	  In	  the	  later	  stages	  of	  the	  disease,	  the	  severity	  of	  bone	  and	  cartilage	  damage	  has	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functional	  implications,	  with	  many	  studies	  demonstrating	  the	  association	  between	  increasing	  joint	  destruction	  and	  progressive	  decline	  in	  physical	  function	  over	  time	  (9).	  	  Serological	  markers	  may	  predict	  the	  progression	  of	  the	  disease.	  Presence	  of	  rheumatoid	  factor	  (RF)	  is	  associated	  with	  general	  radiographic	  progression	  (10,	  11).	  Presence	  of	  anti-­‐citrullinated	  protein	  antibodies	  (ACPA)	  is	  another,	  independent	  predictor	  of	  radiographic	  damage	  (11,	  12).	  	  
GENERAL  PATHOGENESIS  AND  RISK  FACTORS  The	  pathogenesis	  of	  RA	  is	  not	  completely	  understood.	  External	  factors,	  such	  as	  cigarette	  smoking,	  infection,	  or	  trauma,	  seem	  to	  trigger	  an	  autoimmune	  reaction	  resulting	  in	  synovial	  hypertrophy	  and	  chronic	  joint	  inflammation	  along	  with	  the	  potential	  for	  extra-­‐articular	  manifestations	  in	  genetically	  susceptible	  individuals	  (13).	  	  The	  risk	  of	  developing	  RA	  depends	  on	  genetic	  and	  environmental	  factors.	  Recent	  theories	  of	  the	  genetic	  factors	  of	  RA	  propose	  that	  antigens	  in	  RA	  are	  modified	  by	  a	  process	  called	  citrullination.	  This	  process	  involves	  post-­‐translational	  modification	  of	  the	  amino	  acid	  arginine	  to	  citrulline.	  This	  modification	  breaks	  the	  tolerance	  that	  permits	  antibody	  formation	  against	  these	  antigens.	  Therefore,	  genetic	  risk	  factors	  in	  RA	  affect	  both	  ACPA-­‐positive	  and	  ACPA-­‐negative	  forms	  of	  the	  disease	  (14).	  On	  the	  other	  hand,	  environmental	  risk	  factors	  such	  as	  smoking	  predominate	  the	  development	  of	  RA,	  but	  their	  effects	  seem	  limited	  to	  patients	  with	  the	  ACPA-­‐positive	  form	  of	  the	  disease	  (15).	  Other	  possible	  environmental	  risk	  factors	  include	  coffee	  intake,	  low	  vitamin	  D	  levels,	  use	  of	  oral	  contraceptives,	  and	  low	  socioeconomic	  status,	  though	  supporting	  evidence	  for	  these	  other	  factors	  is	  weak	  (16).	  In	  the	  synovium,	  synovial	  cell	  hyperplasia	  and	  endothelial	  cell	  activation	  are	  early	  events	  in	  the	  pathologic	  process	  that	  progresses	  to	  uncontrolled	  chronic	  inflammation	  and	  consequent	  cartilage	  and	  bone	  destruction	  in	  RA.	  Activated	  CD4+	  T	  cells,	  B	  cells,	  mononuclear	  phagocytes,	  fibroblasts,	  osteoclasts,	  and	  neutrophils	  play	  major	  cellular	  roles	  in	  the	  pathophysiology	  of	  RA.	  On	  a	  molecular	  level,	  patients	  with	  RA	  have	  shown	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abnormal	  production	  and	  release	  of	  numerous	  cytokines	  like	  tumor	  necrosis	  factor	  (TNF),	  interleukin	  1	  beta	  (IL-­‐1β), 	  and	  interleukin	  6	  (IL-­‐6);	  chemokines;	  and	  other	  inflammatory	  mediators,	  such	  as	  serotonin(17,	  18).	  	  In	  addition,	  CD4+	  T	  cells	  may	  inappropriately	  recognize	  the	  human	  leukocyte	  antigen-­‐DR	  (HLA-­‐DR)	  autoantigen	  on	  the	  surface	  of	  antigen-­‐presenting	  cells.	  This	  activates	  the	  T	  cell,	  stimulating	  a	  release	  of	  cytokines	  that	  directly	  activates	  synovial	  macrophages	  (18).	  Additionally,	  T	  cells	  also	  activate	  B	  cells,	  which	  release	  antibodies,	  including	  RF.	  This	  may	  then	  lead	  to	  formation	  of	  immune	  complexes,	  resulting	  in	  activation	  of	  the	  immune	  system	  including	  further	  release	  of	  proinflammatory	  cytokines	  (19).	  Cells	  such	  as	  activated	  synovial	  macrophages,	  for	  instance,	  release	  large	  amounts	  of	  TNF	  and	  IL-­‐1	  into	  the	  synovium.	  These	  cytokines	  stimulate	  synoviocytes	  and	  chondrocytes	  in	  the	  cartilage	  to	  release	  matrix	  metalloproteases	  such	  as	  collagenase	  and	  other	  proteases	  which,	  in	  turn,	  degrade	  components	  of	  the	  cartilage	  matrix.	  Increased	  synoviocyte	  proliferation	  culminates	  in	  an	  overgrowth	  of	  synovial	  tissue,	  known	  as	  pannus	  (20-­‐22).	  TNF	  and	  IL-­‐1	  also	  play	  pivotal	  cytokine-­‐mediated	  roles	  in	  the	  destruction	  of	  bone	  and	  cartilage	  in	  RA	  by	  activating	  osteoclasts	  to	  resorb	  bone.	  In	  addition,	  IL-­‐1	  impairs	  bone	  and	  cartilage	  repair	  (18,	  23).	  The	  inflammatory	  process	  is	  usually	  tightly	  regulated,	  involving	  both	  mediators	  that	  initiate	  and	  maintain	  inflammation	  and	  mediators	  that	  shut	  the	  process	  down.	  In	  states	  of	  chronic	  inflammation,	  an	  imbalance	  between	  these	  two	  mediator	  types	  leaves	  inflammation	  uncontrolled,	  resulting	  in	  cellular	  damage.	  In	  the	  case	  of	  RA,	  this	  damage	  is	  manifested	  by	  the	  destruction	  of	  cartilage	  and	  bone	  (24).	  	  
CYTOKINES  Cytokines	  are	  extracellular	  peptides	  that	  influence	  nearly every	  cell	  type	  via	  surface	  receptors.	  Their	  essential	  role	  is	  activation	  and	  maintenance	  of	  immune system	  mechanisms	  including	  the	  inflammatory	  reaction.	  They	  also	  act	  as mediators	  of	  pathology	  in	  infectious,	  inflammatory,	  and	  immune	  diseases	  (25,	  26).	  Cytokines	  are	  involved	  in	  processes	  like	  inflammation	  and	  modulation	  of	  bone	  remodeling	  and	  turnover.	  Cytokines	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play	  important	  roles	  in	  the	  pathology	  of	  RA	  by	  mediating	  acute and	  chronic	  inflammation	  and	  the	  destruction	  of	  cartilage	  and	  bone	  tissue.	  There	  are	  proinflammatory	  cytokines	  and	  anti-­‐inflammatory	  cytokines,	  receptors,	  and	  factors	  that	  constitute	  the	  endogenous	  cytokine	  control	  system	  (23,	  27,	  28).	  The	  activity	  of	  cytokines	  is	  often	  redundant,	  with	  the	  same	  functions	  being	  modulated	  by	  different	  cytokines.	  Cytokines	  are	  often	  released	  in	  a	  cascade:	  one	  cytokine	  will	  stimulate	  its	  target	  cells	  to	  produce	  and	  release	  other	  cytokines	  as	  well	  as	  more	  of	  the	  initiating	  cytokine	  in	  a	  positive	  feedback	  loop.	  However,	  certain	  cytokines	  can	  also	  act	  synergistically	  or	  antagonistically	  (29).	  TNF	  and	  IL-­‐1	  play	  a	  central	  role	  in	  inflammatory	  responses	  as	  shown	  by	  the	  effect	  of	  clinical	  administration	  of	  their	  antagonists,	  such	  as	  monoclonal	  antibodies	  to	  TNF	  (e.g.,	  infliximab	  or	  adalimumab),	  TNFsRII	  (e.g.,	  etanercept),	  and	  the	  IL-­‐1	  receptor	  antagonist	  (IL-­‐1ra,	  e.g.,	  anakinra).	  These	  antagonists	  block	  a	  variety	  of	  acute	  and	  chronic	  responses,	  and	  some	  are	  now	  used	  to	  treat	  RA	  as	  well	  as	  other	  chronic	  inflammatory	  diseases.	  In	  RA,	  TNF	  and	  IL-­‐1	  levels	  are	  increased	  both	  locally	  in	  the	  synovium	  and	  synovial	  fluid	  and	  systemically	  in	  the	  blood	  (25,	  30),	  where	  they	  have	  been	  associated	  with	  pain	  as	  well	  as	  cartilage	  and	  bone	  tissue	  destruction	  (Fig.	  2).	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Figure	  2.	  Mechanisms	  of	  bone	  tissue	  destruction	  in	  arthritis.	  Cells	  from	  rheumatoid	  
arthritis	  (RA)	  synovium	  produce	  factors	  that	  influence	  osteoclast	  differentiation	  and	  
activation	  in	  various	  ways.	  Activated	  macrophages	  produced	  tumor	  necrosis	  factor	  
(TNF)	  and	  interleukin	  1	  (IL-­‐1).	  This	  TNF	  promotes	  bone	  destruction	  by	  upregulating	  
the	  production	  of	  RANKL	  and	  the	  macrophage	  colony-­‐stimulating	  factor	  from	  
osteoblasts,	  and	  by	  augmenting	  differentiation	  into	  osteoclasts.	  The	  bone	  tissue	  is	  
destroyed	  by	  the	  result	  of	  massive	  infiltration	  of	  immune	  cells,	  proliferative	  vessels,	  
and	  increased	  numbers	  of	  osteoclasts.	  (Reprinted	  with	  permission	  from	  Mosby	  
Elsevier).	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Tumor	  necrosis	  factor	  Tumor	  necrosis	  factor	  (TNF)	  seems	  to	  play	  a	  dominant	  role	  in	  directing	  the	  inflammatory	  process	  and	  immune	  response.	  TNF	  is	  mainly	  produced	  by	  activated	  T-­‐cells	  and	  macrophages	  in	  the	  inflamed	  synovium	  (31,	  32)	  and	  modulates	  the	  inflammatory	  response.	  Moreover,	  TNF	  regulates	  the	  production	  of	  other	  proinflammatory	  cytokines	  such	  as	  IL-­‐1	  and	  IL-­‐6	  (33).	  Patients	  with	  RA	  have	  increased	  TNF	  in	  their	  synovial	  fluid	  and	  in	  the	  membrane	  (34).	  	  TNF	  can	  promote	  pain.	  Nociceptive	  pain	  in	  joints	  occurs	  with	  the	  activation	  and	  sensitization	  of	  neurons	  through	  TNF	  and	  IL-­‐1	  (35).	  TNF	  promotes	  inflammation,	  activation	  of	  chemokines,	  and	  upregulation	  of	  other	  receptors	  (35).	  This	  results	  in	  modification	  of	  the	  neurons	  of	  the	  ganglia	  causing	  chronic	  persistent	  pain	  (36).	  TNF	  also	  promotes	  inflammation	  by	  stimulating	  fibroblasts	  to	  express	  adhesion	  molecules,	  such	  as	  intercellular	  adhesion	  molecule	  1	  (37).	  These	  adhesion	  molecules	  interact	  with	  their	  respective	  ligands	  on	  the	  surface	  of	  leukocytes,	  resulting	  in	  increased	  transport	  of	  leukocytes	  to	  inflammatory	  sites,	  including	  the	  joints	  in	  patients	  with	  RA	  (24).	  Independent	  of	  its	  role	  in	  inflammation,	  TNF	  can	  regulate	  osteoclast	  differentiation	  and	  function	  either	  directly	  or	  indirectly	  (38,	  39).	  Individuals	  with	  RA	  have	  elevated	  levels	  of	  TNF	  in	  their	  synovial	  fluid	  as	  well	  as	  their	  plasma,	  and	  they	  play	  an	  important	  role	  in	  the	  inflammation	  and	  bone	  tissue	  destruction	  that	  are	  hallmarks	  of	  RA	  (29).	  	  
Interleukin-­‐1	  The	  IL-­‐1	  family	  members	  (IL-­‐1α,	  IL-­‐1β,	  IL-­‐1ra)	  are	  very	  potent	  cytokines.	  IL-­‐1	  and	  TNF	  share	  multiple	  proinflammatory	  effects	  and	  both	  potentiate	  each	  other	  (40).	  IL-­‐1ra	  binds	  with	  high	  avidity	  to	  IL-­‐1	  receptors	  but	  does	  not	  activate	  cells	  (41).	  IL-­‐1ra	  is	  strongly	  associated	  with	  IL-­‐1β	  release	  and	  is	  related	  to	  the	  severity	  of	  TMJ	  arthritis	  (42-­‐46).	  	  IL-­‐1β	  is	  produced	  by	  activated	  macrophages	  and	  synovial	  fibroblasts	  and	  is	  also	  produced	  by	  activated	  monocytes	  and	  osteoblasts	  during	  inflammation	  (46,	  47).	  The	  effects	  of	  IL-­‐1β	  on	  osteoclasts	  and	  osteoblasts,	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including	  osteoclast	  differentiation	  and	  activation,	  can	  induce	  and	  maintain	  bone	  resorption	  (48).	  IL-­‐1	  correlates	  with	  high	  disease	  activity	  and	  joint	  destruction	  (49,	  50).	  A	  detectable	  level	  of	  IL-­‐1β	  in	  the	  TMJ	  synovial	  fluid	  may	  be	  an	  indicator	  of	  bone	  tissue	  destruction	  in	  polyarthritic	  conditions	  (49).	  Moreover,	  inflammatory	  activity	  in	  RA	  knee	  joints	  is	  also	  related	  to	  local	  level	  of	  IL-­‐1β	  (51).	  Low	  levels	  of	  IL-­‐1ra	  in	  TMJ	  synovial	  fluid	  are	  associated	  with	  TMJ	  pain	  on	  movement,	  probably	  due	  to	  insufficient	  IL-­‐1β	  control	  by	  IL-­‐1ra	  (52,	  53).	  
Soluble	  TNF	  and	  IL-­‐1	  receptors	  Levels	  of	  the	  anti-­‐inflammatory	  TNFsRII	  and	  IL-­‐1sRII	  increase	  dramatically	  during	  inflammation.	  Cell-­‐surface	  type	  II	  IL-­‐1	  receptors	  act	  as	  decoy	  receptors	  with	  anti-­‐inflammatory	  effects	  (54).	  In	  RA,	  these	  receptors	  have	  been	  found	  in	  the	  blood	  and	  synovial	  fluid	  (55)	  while	  elevated	  levels	  of	  IL-­‐1sRII	  have	  been	  found	  in	  plasma	  and	  synovial	  fluid	  (47,	  52,	  56).	  High	  levels	  of	  IL-­‐1sRII	  in	  the	  TMJ	  synovial	  fluid	  have	  been	  associated	  with	  only	  a	  minor	  degree	  of	  joint	  destruction	  or	  none	  at	  all	  (57).	  Anti-­‐inflammatory	  cytokines	  are	  present	  in	  TMJ	  synovial	  fluid	  in	  chronic	  arthritis	  (55).	  	  
SYSTEMIC  INFLAMMATORY  ACTIVITY  The	  erythrocyte	  sedimentation	  rate	  (ESR),	  together	  with	  the	  CRP	  levels	  provide	  a	  basis	  for	  estimating	  systemic	  inflammatory	  activity	  in	  RA.	  These	  markers	  are	  associated	  with	  the	  occurrence,	  progression,	  and	  prediction	  of	  articular	  bone	  tissue	  resorption	  in	  patients	  with	  RA	  (58-­‐62).	  	  
Erythrocyte	  sedimentation	  rate	  Along	  with	  other	  factors,	  cytokine	  release	  increases	  the	  ESR.	  The	  ESR	  is	  one	  of	  several	  useful	  measures	  for	  assessing	  the	  severity	  of	  RA,	  especially	  in	  later	  stages	  (58,	  63,	  64).	  A	  high	  ESR	  has	  been	  associated	  with	  difficulty	  in	  performing	  physical	  activities.	  Elevated	  ESRs	  also	  indicate	  a	  poor	  prognosis	  in	  systemic	  inflammatory	  disease	  (63).	  However,	  ESR	  has	  limited	  prognostic	  value	  as	  a	  single	  marker	  in	  early	  RA	  (65,	  66).	  For	  example,	  an	  evaluation	  of	  the	  prognostic	  value	  of	  the	  ESR	  for	  radiographic	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progression	  in	  patients	  with	  RA	  found	  that	  the	  value	  was	  too	  low	  to	  be	  used	  as	  a	  single	  prognostic	  marker	  in	  clinical	  practice	  (67).	  	  
C-­‐reactive	  protein	  CRP	  is	  an	  acute	  phase	  protein	  produced	  in	  the	  liver	  upon	  stimulation	  by	  increased	  levels	  of	  cytokines	  in	  the	  blood,	  such	  as	  TNF,	  IL-­‐1,	  and	  IL-­‐6	  (68).	  CRP	  is	  sensitive	  to	  inflammation	  and,	  as	  such,	  inflammation	  triggers	  rapid	  production	  and	  release	  of	  CRP,	  which	  also	  decreases	  rapidly	  when	  inflammation	  subsides.	  	  Several	  studies	  have	  shown	  a	  relationship	  between	  CRP	  levels	  and	  radiographic	  joint	  damage,	  in	  hand	  joints	  for	  example	  (67,	  69).	  High	  CRP	  is	  related	  to	  radiographic	  progression	  of	  TMJ	  bone	  tissue	  resorption	  in	  patients	  with	  RA	  (70,	  71).	  	  
Disease	  Activity	  Score	  28	  DAS28,	  which	  includes	  a	  28-­‐joint	  count	  of	  tender	  or	  swollen	  joints,	  is	  a	  routine	  measure	  in	  both	  clinical	  practice	  and	  research	  (72).	  DAS28	  combines	  data	  from	  the	  swollen	  joint	  count,	  tender	  joint	  count,	  CRP	  levels	  or	  the	  ESR,	  and	  the	  patient’s	  self-­‐evaluation	  of	  general	  health.	  It	  excludes	  assessment	  of	  the	  foot	  and	  ankle	  joints	  because,	  in	  these	  joints,	  tenderness	  and	  swelling	  may	  be	  confused	  with	  other	  disorders	  (72,	  73).	   
SEROLOGICAL  BIOMARKERS    
Rheumatoid	  factor	  RF	  is	  an	  Immunoglobulin	  M	  (IgM)	  autoantibody	  against	  the	  fragment	  crystallizable	  (FC)	  portion	  of	  human	  IgG	  (74).	  It	  can	  be	  detected	  in	  60-­‐80%	  of	  patients	  with	  RA	  and	  is	  a	  well-­‐recognized	  predictor	  of	  a	  poor	  prognosis	  in	  RA	  (75-­‐77).	  RF	  contributes	  to	  the	  disease	  by	  activating	  the	  immune	  system	  in	  the	  synovial	  tissues	  (78);	  RF	  binds	  to	  the	  Fc	  portion	  of	  IgG,	  thereby	  activating	  the	  immune	  system	  via	  antigen-­‐presentation	  cells	  and	  by	  activating	  platelets	  that	  release,	  for	  example,	  serotonin	  upon	  activation	  (74)	  In	  the	  TMJ,	  radiographic	  signs	  of	  bone	  tissue	  resorption	  in	  the	  late	  phase	  of	  RA	  (79)	  are	  related	  to	  RF	  levels	  in	  serum.	  One	  study	  on	  patients	  with	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recent-­‐onset	  RA	  shows	  that	  the	  presence	  of	  RF	  predicted	  more	  severe	  disease	  outcomes	  (80).	  High	  disease	  activity	  and	  presence	  of	  RF	  were	  the	  strongest	  factors	  predicting	  a	  poor	  prognosis	  in	  patients	  with	  RA	  (67).	  	  
Antibodies	  against	  citrullinated	  proteins	  	  ACPA	  are	  present	  in	  the	  vast	  majority	  of	  patients	  with	  established	  RA	  (97%)	  (81).	  These	  autoantibodies	  recognize	  proteins	  or	  peptides	  where	  the	  amino	  acid	  arginine	  is	  changed	  into	  citrulline	  through	  a	  process	  of	  posttranslational	  modification,	  mediated	  by	  peptidyl	  arginine	  deiminase	  enzymes.	  High	  calcium	  levels	  can	  activate	  these	  enzymes	  through	  inflammation	  or	  by	  smoking	  for	  example	  (82,	  83).	  Citrullinated	  proteins	  are	  present	  in	  various	  inflamed	  tissues,	  including	  the	  synovial	  tissue	  of	  patients	  with	  RA	  (84,	  85).	  ACPA	  activates	  the	  immune	  system	  when	  it	  detects	  a	  citrullinated	  peptide	  (86).	  	  
The	  temporomandibular	  joint	  in	  rheumatoid	  arthritis	  TMJ	  involvement	  in	  RA	  is	  common	  with	  a	  prevalence	  of	  30-­‐65%,	  depending	  on	  patient	  selection,	  diagnostic	  criteria,	  and	  techniques	  used	  (87-­‐89).	  The	  most	  important	  clinical	  consequences	  of	  TMJ	  in	  RA	  are	  pain,	  TMJ	  clicking	  and	  locking,	  limitation	  in	  opening	  the	  mouth	  (90),	  and	  functional	  disability,	  such	  as	  pain	  during	  jaw	  movement	  and	  loading	  or	  an	  anterior	  open	  bite	  due	  to	  TMJ	  bone	  tissue	  resorption.	  Involvement	  of	  the	  TMJ	  in	  RA	  can	  restrict	  jaw	  function	  due	  to	  movement-­‐related	  pain	  or	  limitation	  of	  condylar	  translation.	  An	  anterior	  opening	  of	  the	  bite	  due	  to	  articular	  cartilage	  and	  bone	  tissue	  destruction	  may	  also	  develop.	  These	  consequences	  may	  have	  a	  significant	  impact	  on	  the	  daily	  activities	  and	  quality	  of	  life	  of	  the	  affected	  patients	  (91).	  
Temporomandibular	  joint	  pain	  RA	  pain	  arises	  from	  peripheral	  and	  central	  mechanisms	  (92).	  In	  RA,	  peripheral	  nociceptors	  are	  activated	  and	  sensitized	  by	  inflammatory	  mediators	  like	  cytokines	  released	  at	  the	  inflammatory	  site.	  Central	  pain	  mechanisms	  are	  also	  involved	  in	  RA	  pain	  (92).	  Inflamed	  joints,	  as	  well	  as	  remote	  nonarticular	  sites,	  show	  general	  reductions	  in	  pressure	  and	  thermal	  pain	  thresholds	  and	  also	  increases	  in	  pain	  sensitivity	  (92).	  Because	  RA	  is	  a	  systemic	  disease	  that	  expresses	  a	  major	  part	  of	  its	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pathology	  in	  the	  synovial	  tissues,	  systemic	  mechanisms,	  as	  well	  as	  local	  mechanisms,	  can	  modulate	  TMJ	  pain	  in	  RA.	  Proinflammatory	  cytokines	  such	  as	  TNF,	  as	  well	  as	  soluble	  anti-­‐inflammatory	  cytokines	  such	  as	  IL-­‐1sRII,	  are	  involved	  in	  the	  pathophysiology	  of	  RA.	  Alstergren	  et	  al.	  (52)	  show	  that,	  in	  RA,	  the	  TMJ	  pressure	  pain	  threshold	  depends	  on	  systemic,	  rather	  than	  local,	  mediators.	  The	  study	  also	  shows	  that	  seropositive	  and	  seronegative	  patients	  differ	  not	  only	  concerning	  systemic	  inflammatory	  activity,	  as	  would	  be	  expected,	  but	  also	  in	  TMJ	  pain	  on	  mandibular	  movement.	  Moreover,	  the	  degree	  of	  local	  TMJ	  inflammatory	  activity,	  as	  indicated	  by	  the	  investigated	  inflammatory	  mediators	  in	  the	  synovial	  fluid,	  did	  not	  influence	  the	  TMJ	  pressure	  pain	  threshold.	  Thus,	  the	  TMJ	  pressure	  pain	  threshold	  is	  modulated	  by	  systemic	  rather	  than	  local	  inflammatory	  mediators,	  which	  suggests	  that	  it	  is	  unrelated	  or	  only	  weakly	  related	  to	  other	  TMJ	  pain	  parameters	  in	  patients	  with	  RA.	  RF-­‐dependent	  systemic	  modulation,	  in	  combination	  with	  local	  factors,	  seems	  to	  account	  for	  TMJ	  pain	  in	  patients	  with	  RA. RA	  frequently	  affects	  the	  TMJ,	  and	  often	  early	  in	  the	  course	  of	  the	  disease.	  Aliko	  et	  al.	  (89)	  found	  that	  65%	  of	  patients	  with	  RA	  have	  TMJ	  symptoms.	  TMJ	  pain,	  especially	  on	  movement	  or	  loading,	  is	  the	  most	  common	  clinical	  finding	  (93).	  TMJ	  pain	  due	  to	  involvement	  of	  RA	  modulates	  both	  via	  local	  mechanisms	  (such	  as	  mediators	  released	  in	  the	  synovial	  tissues)	  and	  systemic	  factors	  (such	  as	  circulating	  mediators	  that	  act	  on	  the	  synovial	  tissues	  or	  pain-­‐associated	  mechanisms	  in	  the	  central	  nervous	  system)	  (94-­‐96).	  For	  example,	  Alstergren	  et	  al.	  (2008)	  (52)	  found	  that	  TMJ	  pressure	  pain	  is	  determined	  by	  systemic	  rather	  than	  local	  mediators	  in	  RA.	  Pain	  in	  the	  jaw–face–head	  region	  correlates	  with	  an	  impaired	  state	  of	  general	  health,	  and	  generalized	  arthritis	  may	  contribute	  to	  TMD	  pain	  (97).	  	  Clinically,	  determining	  the	  relative	  influence	  of	  systemic	  and	  local	  factors	  may	  affect	  the	  choice	  of	  treatment	  since	  the	  results	  of	  systemic	  treatment,	  with	  TNF	  blockers,	  for	  example,	  seem	  rather	  variable	  in	  reducing	  TMJ	  pain	  (55,	  98).	  	  
 12 
Temporomandibular	  joint	  tissue	  destruction	  	  The	  severity	  of	  TMJ	  arthritis	  in	  RA	  correlates	  strongly	  with	  the	  severity	  of	  general	  disease.	  TMJ	  involvement	  is	  common	  in	  late-­‐stage	  RA,	  depending	  on	  the	  patients’	  diagnostic	  criteria	  (87,	  88).	  The	  TMJ	  is	  often	  affected	  in	  patients	  with	  RA,	  with	  about	  30-­‐50%	  of	  patients	  experiencing	  TMJ	  pain	  or	  impaired	  function	  (99).	  Radiographic	  change,	  such	  as	  erosion,	  is	  more	  common	  in	  patients	  with	  RA	  (100,	  101)	  than	  with	  other	  inflammatory	  diseases.	  Erosion	  of	  the	  TMJ	  correlates	  with	  decreased	  mandibular	  mobility,	  anterior	  open	  bite,	  and	  difficulty	  chewing	  (102).	  Markers	  of	  inflammation	  such	  as	  CRP,	  ESR,	  RF,	  and	  thrombocyte	  particle	  count	  (TPC)	  	  are	  all	  associated	  with	  the	  severity	  of	  TMJ	  in	  RA	  (50,	  70,	  87).	  The	  destructive	  process	  does	  not	  necessarily	  correlate	  with	  local	  clinical	  signs	  and	  symptoms	  because	  a	  large	  proportion	  of	  asymptomatic	  patients	  show	  radiographic	  signs	  of	  bone	  tissue	  resorption	  (79,	  103,	  104).	  	  IL-­‐1β	  is	  present	  in	  the	  synovial	  tissue	  and	  fluids	  of	  patients	  with	  RA	  and	  contributes	  to	  bone	  tissue	  and	  cartilage	  destruction	  in	  TMJ	  arthritis	  (42,	  105).	  Patients	  with	  chronic	  inflammatory	  joint	  disease	  and	  detectable	  levels	  of	  IL-­‐1β	  in	  TMJ	  synovial	  fluid	  exhibit	  greater	  extents	  of	  radiographic	  changes	  than	  patients	  with	  undetectable	  IL-­‐1β	  (70,	  100,	  106).	  	  Progressive	  articular	  cartilage	  degradation	  and	  bone	  tissue	  resorption	  also	  characterize	  RA,	  resulting	  in	  loss	  of	  function	  in	  the	  musculoskeletal	  system.	  If	  untreated,	  this	  may	  lead	  to	  severe	  disability,	  contributing	  to	  poor	  quality	  of	  life	  for	  these	  patients	  (107,	  108).	  	  
Consequences	  of	  chronic	  pain	  in	  rheumatoid	  arthritis	  Pain	  is	  a	  major	  determinant	  of	  quality	  of	  life	  for	  patients	  with	  RA.	  It	  is	  also	  the	  most	  common	  reason	  for	  patients	  with	  RA	  to	  seek	  treatment	  (109).	  Pain	  is	  also	  strongly	  and	  negatively	  associated	  with	  other	  patient-­‐reported	  outcomes	  and	  quality	  of	  life	  (109).	  Voog	  et	  al.	  2003	  (91)	  found	  that	  TMJ	  pain	  was	  associated	  with	  difficulties	  in	  performing	  physical	  exercise	  and	  other	  daily	  activities.	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Activities	  of	  daily	  living	  Activities	  of	  daily	  living	  (ADL)	  refers	  to	  the	  basic	  tasks	  of	  everyday	  life	  like	  eating,	  bathing,	  dressing,	  using	  the	  toilet,	  and	  walking:	  the	  activities	  required	  for	  personal	  self-­‐care	  and	  independent	  living.	  The	  ADL	  scale	  is	  a	  10-­‐item	  reliable	  and	  valid	  self-­‐reported	  measure	  (110).	  Voog	  et	  al.	  2003	  (91)	  used	  the	  ADL	  to	  measure	  how	  TMJ	  pain	  influenced	  activities	  in	  daily	  life.	  The	  last	  item	  in	  their	  questionnaire	  was	  a	  summary	  question	  about	  TMJ	  pain’s	  impact	  on	  daily	  activities.	  	  
Quality	  of	  life	  There	  is	  some	  evidence	  suggesting	  the	  impact	  of	  pain	  in	  other	  chronic	  joint	  inflammatory	  diseases,	  (111)	  which	  may	  indicate	  a	  decrease	  in	  quality	  of	  life	  for	  patients	  with	  RA.	  Due	  to	  pain	  and	  functional	  limitation,	  RA	  affects	  many	  aspects	  of	  daily	  life	  (112).	  TMJ	  pain	  seems	  to	  affect	  daily	  activities	  in	  general,	  which	  may	  also	  influence	  quality	  of	  life.	  Voog	  et	  al.	  (91)	  found	  that	  TMJ	  pain	  can	  contribute	  to	  work	  disability,	  a	  frequent	  problem	  in	  patients	  with	  RA.	  	  
Magnetic	  resonance	  imaging	  Magnetic	  resonance	  imaging	  (MRI),	  together	  with	  computerized	  tomography	  (CT)	  and	  cone-­‐beam	  CT	  (CBCT),	  are	  the	  primary	  methods	  for	  assessing	  articular	  bone	  tissue	  changes	  and	  changes	  in	  the	  TMJ	  (113,	  114).	  MRI	  has	  also	  been	  shown	  to	  be	  valuable	  for	  evaluating	  soft	  tissue	  changes	  in	  the	  TMJ	  in	  RA	  (105,	  115,	  116).	  Since	  MRI	  uses	  no	  ionizing	  radiation,	  use	  of	  MRI	  is	  often	  preferable	  to	  CT	  when	  either	  method	  could	  yield	  the	  same	  information	  (115).	  	  Radiographic	  involvement	  of	  the	  TMJ	  occurs	  in	  45-­‐71%	  of	  patients	  with	  RA	  (70,	  117,	  118),	  while	  condyle	  resorption	  is	  found	  in	  two-­‐thirds	  of	  the	  TMJs	  of	  patients	  with	  RA	  (114,	  115).	  A	  radiographic	  sign	  of	  erosion	  is	  generally	  considered	  to	  indicate	  active	  bone	  resorption	  and	  ongoing	  inflammatory	  activity	  (50,	  117).	  In	  addition,	  TMJ	  disc	  displacement	  is	  common	  and	  is	  associated	  with	  RA	  (115).	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Aims	  The	  overall	  aims	  of	  this	  project	  were	  to	  study	  TMJ	  pain	  and	  bone	  tissue	  destruction	  in	  relation	  to	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines	  and	  systemic	  inflammatory	  activity,	  as	  well	  as	  the	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  and	  quality	  of	  life.	  The	  specific	  aims	  were	  to	  investigate,	  in	  patients	  with	  RA:	  
§ The	  impact	  of	  TMJ	  pain	  and	  inflammation	  on	  daily	  activities	  and	  quality	  of	  life	  in	  relation	  to	  systemic	  inflammatory	  activity.	  
§ The	  relative	  amounts	  of	  TNF	  and	  IL-­‐1	  compared	  to	  their	  respective	  soluble	  receptors	  in	  TMJ	  synovial	  fluid	  and	  blood	  in	  relation	  to	  TMJ	  pain.	  
§ The	  relative	  amounts	  of	  TNF	  and	  IL-­‐1	  compared	  to	  their	  respective	  soluble	  receptors	  in	  TMJ	  synovial	  fluid	  and	  blood	  in	  relation	  to	  TMJ	  bone	  tissue	  destruction	  and	  disc	  displacement.	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MATERIALS	  AND	  METHODS	  
Patients	  We	  invited	  33	  consecutive	  outpatients	  with	  RA	  from	  the	  Department	  of	  Rheumatology	  at	  Dr.	  Bakhsh	  Hospital,	  Jeddah,	  Saudi	  Arabia,	  to	  participate	  in	  the	  study.	  Patients	  received	  the	  invitation	  at	  their	  first	  visit	  or	  follow-­‐up	  at	  the	  rheumatology	  clinic	  without	  considering	  whether	  they	  had	  TMJ	  pain.	  Inclusion	  criteria	  required	  patients	  to	  have	  a	  diagnosis	  of	  RA	  according	  to	  the	  1987	  criteria	  of	  the	  American	  College	  of	  Rheumatology	  (6).	  We	  excluded	  patients	  younger	  than	  20	  years,	  those	  with	  current	  malignancies,	  those	  who	  had	  had	  TMJ	  surgery	  or	  trauma	  within	  the	  past	  year,	  and	  those	  who	  had	  had	  an	  intra-­‐articular	  corticosteroid	  injection	  in	  the	  TMJ	  in	  the	  past	  six	  months.	  Seven	  patients	  declined	  to	  have	  blood	  samples	  taken	  but	  underwent	  the	  clinical	  examination.	  This	  meant	  that	  Study	  I	  included	  26–33	  patients	  (33	  for	  the	  clinical	  measures	  and	  26	  for	  the	  blood	  sample	  measures)	  and	  Study	  II	  included	  26	  patients.	  Four	  more	  patients	  refused	  the	  MR	  examination,	  so	  Study	  III	  included	  only	  22	  patients	  (Table	  1).	  	  	  All	  patients	  received	  verbal	  and	  written	  information	  about	  the	  project	  before	  consenting	  to	  participate.	  The	  ethics	  committee	  of	  the	  Ministry	  of	  Health,	  Jeddah,	  Saudi	  Arabia	  (H-­‐02-­‐J-­‐002)	  approved	  the	  study	  design,	  methods	  used,	  and	  patient	  selection	  and	  allowed	  this	  project	  to	  be	  conducted	  at	  Dr.	  Bakhsh	  Hospital.	  All	  subjects	  gave	  their	  informed	  consent	  before	  participation.	  
Clinical	  examination	  Each	  patient	  underwent	  clinical	  examination	  by	  one	  calibrated	  operator	  (NA)	  who	  had	  no	  knowledge	  of	  the	  patient’s	  general	  or	  rheumatologic	  history	  or	  status	  before	  the	  examination.	  The	  same	  clinical	  examination	  had	  been	  used	  in	  several	  previous	  studies	  (91,	  105).	  In	  addition	  to	  general	  information	  on	  age,	  sex,	  duration	  of	  RA	  diagnosis	  and	  TMJ	  symptoms,	  smoking	  habits,	  and	  medication,	  the	  examination	  assessed	  the	  following	  variables.	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The	  attending	  rheumatologist	  performed	  the	  DAS28	  on	  the	  same	  day	  as	  the	  TMJ	  examination.	  A	  DAS28	  score	  >5.1	  indicates	  high	  disease	  activity,	  3.2–5.1	  indicates	  moderate	  disease	  activity,	  2.6–3.2	  indicates	  low	  disease	  activity,	  and	  <2.6	  indicates	  remission.	  The	  patients	  answered	  questions	  about	  ongoing	  pain	  in	  nine	  joint	  regions	  besides	  the	  TMJ	  (neck,	  shoulders,	  elbows,	  hands,	  upper	  back,	  lower	  back,	  hips,	  knees,	  and	  feet)	  and	  number	  of	  painful	  joint	  regions	  (score	  =	  0–9).	  To	  assess	  TMJ	  pain	  intensity	  during	  the	  past	  week,	  we	  used	  a	  0–10	  numerical	  rating	  scale	  (NRS)	  where	  0	  corresponded	  to	  “No	  pain”	  and	  10	  to	  “Worst	  imaginable	  pain”	  and	  assessed	  each	  TMJ	  at	  rest,	  at	  maximum	  voluntary	  mouth	  opening,	  and	  while	  chewing	  (Studies	  I	  and	  II).	  We	  then	  measured	  in	  mm	  maximum	  voluntary	  mouth	  opening	  capacity,	  laterotrusion	  to	  both	  sides,	  and	  protrusion	  between	  teeth	  11	  and	  41	  with	  a	  vertical	  overbite	  added	  where	  applicable	  (Studies	  I	  and	  II).	  At	  the	  same	  time	  we	  used	  an	  NRS	  (0–10)	  to	  assess	  pain	  intensity	  at	  laterotrusion	  to	  both	  sides,	  and	  protrusion	  (Studies	  I	  and	  II).	  We	  measured	  pain	  threshold	  in	  mm,	  defined	  as	  the	  maximum	  mouth	  opening	  without	  pain	  or	  without	  increase	  in	  any	  ongoing	  pain	  (Studies	  I	  and	  II).	  Statistical	  analysis	  calculated	  the	  sum	  of	  the	  pain	  intensities	  during	  TMJ	  movements	  for	  each	  TMJ	  (maximum	  voluntary	  mouth	  opening,	  lateral	  and	  contralateral	  laterotrusion,	  and	  protrusion)	  for	  a	  total	  score	  of	  0–40.	  	  Tenderness	  to	  digital	  palpation	  with	  a	  force	  of	  10	  N	  (score	  =	  0–3)	  evaluated	  the	  lateral	  and	  posterior	  aspect	  of	  the	  TMJ	  on	  each	  side.	  Patients	  scored	  1	  if	  they	  reported	  tenderness	  upon	  palpation,	  2	  if	  palpation	  also	  caused	  a	  palpebral	  reflex,	  and	  3	  if	  palpation	  caused	  a	  defense	  reaction.	  Statistical	  analysis	  evaluated	  the	  sum	  of	  these	  scores	  for	  each	  TMJ	  (Studies	  I	  and	  II).	  The	  patients	  rated	  the	  impact	  of	  TMJ	  pain	  on	  their	  ability	  to	  perform	  daily	  activities	  and	  on	  the	  quality	  of	  their	  life	  on	  a	  0–10	  NRS	  where	  0	  corresponded	  to	  “no	  impact	  of	  TMJ	  pain	  on	  daily	  activities/quality	  of	  life”	  and	  10	  corresponded	  to	  “maximum	  impact	  of	  TMJ	  pain	  on	  daily	  activities/quality	  of	  life.”	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Temporomandibular	  joint	  synovial	  fluid	  sampling	  TMJ	  synovial	  fluid	  sampling	  used	  the	  procedures	  of	  Alstergren	  et	  al.	  (119),	  a	  scientifically	  validated,	  routine	  method	  developed	  and	  used	  since	  1995	  that	  enables	  determination	  of	  the	  true	  synovial	  fluid	  concentration	  of	  the	  investigated	  mediators	  after	  a	  saline	  wash	  of	  the	  joint	  (Fig.	  3).	  Briefly,	  we	  obtained	  TMJ	  synovial	  fluid	  samples	  by	  washing	  the	  joint	  cavity	  with	  a	  diluted	  washing	  solution	  using	  a	  push-­‐and-­‐pull	  technique.	  The	  washing	  solution	  consisted	  of	  physiological	  saline	  and	  22%	  hydroxocobalamin,	  which	  was	  included	  to	  determine	  the	  amount	  of	  synovial	  fluid	  in	  the	  aspirate.	  This	  would	  have	  enabled	  calculation	  of	  the	  true	  synovial	  fluid	  concentration	  of	  each	  investigated	  mediator.	  However,	  due	  to	  technical	  and	  procedural	  difficulties	  in	  Saudi	  Arabia,	  use	  of	  the	  hydroxocobalamin	  method	  to	  determine	  concentrations	  in	  the	  samples	  was	  not	  possible.	  Thus,	  statistical	  analysis	  used	  the	  ratios	  between	  the	  synovial	  fluid	  sample	  concentrations	  of	  the	  cytokines	  and	  their	  endogenous	  control	  mediators.	  We	  centrifuged	  the	  samples	  (1500	  g	  for	  10	  min	  at	  4°C)	  and	  transferred	  the	  supernatants	  into	  other	  tubes,	  specific	  to	  each	  substance	  to	  be	  analyzed,	  which	  we	  stored	  at	  -­‐80°C	  until	  analysis.	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Figure	  3.	  Using	   the	  push-­‐and-­‐pull	   technique	   to	  wash	   the	   temporomandibular	  
joint	  with	   hydroxocobalamin	   (vitamin	   B12)	   as	   an	   internal	   standard	   to	   enable	  
calculation	  of	  true	  synovial	  fluid	  concentrations.	  The	  upper	  syringe	  contains	  the	  
washing	   solution	   that	   is	   injected	   into	   the	   joint	   compartment,	   in	   1	   mL	   incre-­‐
ments,	   and	   the	   lower	   syringe	   contains	   the	   aspirate	   fluid	   (washing	   solution	   +	  
synovial	  fluid).	  The	  difference	  in	  absorbance	  between	  the	  washing	  solution	  and	  
the	   aspirate	   is	   used	   to	   calculate	   the	   true	   synovial	   fluid	   concentrations	   of	   the	  
various	  mediators.	  
	  Analysis	  determined	  the	  TMJ	  synovial	  fluid	  levels	  of	  the	  cytokines	  TNF	  and	  IL-­‐1ra;	  the	  soluble	  cytokine	  receptors	  TNFsRII	  and	  IL-­‐1sRII;	  and	  CRP,	  ACPA,	  and	  RF.	  Since	  the	  true	  synovial	  concentration	  of	  each	  mediator	  could	  not	  be	  determined	  in	  the	  present	  study,	  we	  used	  the	  ratios	  between	  both	  TNF	  and	  IL-­‐1	  and	  their	  respective	  soluble	  receptors	  II	  (TNF/TNFsRII;	  IL-­‐1ra/IL-­‐1sRII)	  as	  well	  as	  TNF/RF,	  TNF/ACPA,	  TNF/CRP,	  IL-­‐1ra/RF,	  IL-­‐1ra/ACPA,	  and	  IL-­‐1ra/CRP.	  These	  ratios	  are	  fully	  comparable	  between	  cases.	  The	  biological	  meaning	  of	  these	  ratios	  is	  relevant,	  especially	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regarding	  the	  ratios	  between	  TNF	  and	  IL-­‐1	  and	  their	  soluble	  receptors,	  since	  the	  normal	  balance	  between	  the	  proinflammatory	  cytokines	  and	  their	  endogenous	  control	  systems	  is	  disturbed	  in	  inflammation,	  toward	  a	  relative	  excess	  of	  proinflammatory	  cytokines	  (45).	  Our	  studies	  represent	  some	  of	  only	  a	  few	  studies	  investigating	  this	  balance	  and	  its	  contribution	  to	  inflammatory	  activity.	  
Blood	  sampling	  and	  laboratory	  procedures	  Immediately	  after	  the	  clinical	  examination,	  we	  collected	  venous	  blood	  (5	  mL)	  in	  uncoated	  tubes	  and	  left	  them	  at	  room	  temperature	  to	  coagulate	  for	  1	  hour	  before	  centrifuging	  (10	  min	  at	  4°C	  and	  1500	  g).	  We	  stored	  the	  supernatant	  (serum)	  at	  -­‐80°C	  until	  analysis.	  The	  accredited	  Saudi	  Laboratories	  at	  the	  Ministry	  of	  Health	  Research	  Center,	  Jeddah,	  Saudi	  Arabia	  then	  determined	  the	  ESR;	  the	  TPC;	  and	  CRP,	  ACPA,	  and	  RF	  concentrations.	  Our	  analysis	  used	  the	  Westergren	  method	  to	  determine	  ESR	  considering	  levels	  below	  20	  mm/h	  for	  females	  and	  13	  mm/h	  for	  males	  as	  normal.	  The	  particle-­‐enhanced	  turbidimetric	  test	  (Cobas	  Integra	  analyzer;	  Roche,	  Mannheim,	  Germany)	  analyzed	  CRP	  with	  levels	  below	  5	  mg/L	  considered	  normal.	  To	  analyze	  ACPA,	  we	  used	  a	  microparticle	  enzyme	  immunoassay	  for	  semiqualitative	  measurement	  of	  the	  IgG	  class	  of	  autoantibodies	  specific	  for	  citrullinated	  proteins	  in	  human	  serum	  (EL-­‐anti-­‐CCP/2TM;	  TheraTest	  Laboratories	  Inc.,	  Lombard,	  IL,	  USA),	  considering	  levels	  below	  11	  U/ml	  as	  normal.	  The	  direct	  latex	  fixation	  test	  (Architect	  ci4100;	  Abbott	  Laboratories,	  Abbott	  Park,	  IL,	  USA)	  analyzed	  RF,	  with	  levels	  below	  14	  IU/mL	  considered	  normal.	  Analysis	  of	  TPC	  used	  the	  ADVIA®	  2120i	  System	  with	  Autoslide	  streamlined	  workflow	  (Siemens	  Medical	  Solutions	  USA,	  Inc.,	  Malvern,	  PA,	  USA)	  with	  the	  reference	  range	  for	  normal	  values	  at	  150–400	  109/L.	  To	  determine	  the	  concentrations	  of	  cytokines	  and	  cytokine	  receptors	  in	  TMJ	  synovial	  fluid	  and	  blood	  serum,	  we	  used	  commercially	  available	  kits	  (Human	  Tumor	  Necrosis	  Factor	  [TNF]	  ELISA	  Kit,	  Human	  sTNFR2	  ELISA	  Kit,	  Human	  Interleukin	  I	  Receptor	  Antagonist	  [lL-­‐I	  Ra]	  ELISA	  Kit,	  and	  Human	  sTNFR2	  ELISA	  Kit;	  all	  from	  Wkea	  Med	  Supplies	  Corp,	  Changchun,	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China).	  The	  assay	  ranges	  were	  20–400	  ng/L	  for	  TNF,	  20–800	  ng/L	  for	  TNFsRII,	  20–500	  ng/L	  for	  IL-­‐1ra,	  and	  5–180	  pg/ml	  for	  IL-­‐1sRII.	  We	  measured	  ACPA	  concentrations	  in	  the	  TMJ	  synovial	  fluid	  using	  an	  enzyme	  antibody	  immunoassay	  (EL-­‐anti-­‐CCp/2TM;	  TheraTest	  Laboratories	  Inc.,	  Lombard,	  IL,	  USA)	  considering	  levels	  exceeding	  7	  IU/mL	  to	  be	  ACPA	  positive.	  	  
Magnetic	  resonance	  imaging	  Study	  III	  conducted	  an	  MRI	  examination	  of	  the	  TMJ	  region	  in	  both	  closed-­‐	  and	  open-­‐mouth	  positions.	  For	  the	  closed-­‐mouth	  position,	  the	  patients	  closed	  their	  mouths	  with	  their	  teeth	  in	  light	  intercuspid	  contact.	  For	  the	  open-­‐mouth	  position,	  the	  patients	  opened	  their	  mouths	  as	  wide	  as	  possible	  and	  we	  placed	  a	  stepped	  plastic	  bite-­‐block	  between	  the	  upper	  and	  lower	  incisors	  to	  support	  and	  maintain	  a	  stable	  mouth	  opening	  during	  image	  acquisition.	  We	  took	  bilateral	  TMJ	  MR	  images	  within	  one	  week	  after	  the	  clinical	  examination.	  A	  1.5	  Tesla	  Siemens	  Magnetom	  Sonata	  Vision	  (Siemens,	  Erlangen,	  Germany)	  produced	  the	  images	  using	  a	  bilateral	  TMJ	  surface	  coil	  with	  a	  double-­‐echo,	  turbo	  spin-­‐echo	  sequences.	  We	  rendered	  images	  using	  sagittal	  (parallel	  to	  the	  sagittal	  plane)	  and	  coronal	  sections	  using	  proton	  density	  (PD)	  and	  T1-­‐weighted	  algorithms	  for	  analysis.	  	  We	  evaluated	  the	  MRI	  sections	  for	  disc	  position	  and	  for	  presence	  of	  erosions	  within	  the	  condylar	  and	  temporal	  portions	  of	  the	  TMJ,	  defining	  erosion	  as	  a	  loss	  of	  continuity	  of	  the	  articular	  margin	  (Fig.	  4).	  Disc	  positions	  were	  classified	  into	  the	  five	  following	  types:	  i) Normal.	  The	  disc	  is	  in	  the	  sagittal	  plane	  (relative	  to	  the	  superior	  aspect	  of	  the	  condyle);	  the	  border	  between	  the	  low	  signal	  of	  the	  disc	  and	  the	  high	  signal	  of	  the	  retrodiscal	  tissue	  is	  located	  between	  the	  11:30	  and	  12:30	  clock	  positions;	  the	  intermediate	  zone	  in	  the	  sagittal	  plane	  is	  located	  between	  the	  anterior-­‐superior	  aspect	  of	  the	  condyle	  and	  the	  posterior-­‐inferior	  aspect	  of	  the	  articular	  eminence;	  and,	 in	  the	  oblique	  coronal	  plane,	  the	  disc	  is	  centered	  between	  the	  condyle	  and	  the	  eminence	  in	  the	  medial,	  central,	  and	  lateral	  parts.	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ii) Disc	  displacement	  with	  reduction.	  Disc	  location	  is	  displaced	  in	  closed-­‐mouth	  images	  but	  normal	  in	  open-­‐mouth	  images.	  iii) Disc	  displacement	  without	  reduction.	  Disc	  location	  is	  displaced	  in	  closed-­‐mouth	  and	  open-­‐mouth	  images.	  iv) Indeterminate.	  Disc	  location	  is	  unclear.	  v) Invisible.	  Neither	  signal	  intensity	  nor	  outlines	  enable	  a	  structure	  to	  be	  defined	  as	  the	  disc	  in	  closed-­‐	  or	  open-­‐mouth	  views	  (120).	  	  	  	  
	  
Figure	   4.	   T1-­‐weighted	   sagittal	   magnetic	   reso-­‐
nance	  image	  showing	  erosions	  on	  the	  anterior-­‐
superior	   aspect	   of	   the	   temporomandibular	  
joint	  condyle	  head.	  
	  
Statistics	  Analysis	  used	  parametric	  and	  non-­‐parametric	  methods	  where	  applicable.	  Descriptive	  statics	  report	  either	  the	  median	  and	  the	  25th	  and	  75th	  percentiles	  or	  the	  mean	  and	  standard	  deviation	  (SD).	  We	  also	  report	  the	  percentage	  of	  abnormal	  values	  for	  relevant	  variables.	  	  For	  analytical	  statistics,	  we	  calculated	  the	  significance	  of	  differences	  between	  groups	  and	  correlations	  between	  variables	  using	  the	  Mann-­‐
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Whitney	  U-­‐test	  and	  Spearman	  ranked	  correlation	  and	  partial	  correlation	  tests.	  In	  Studies	  I	  and	  II,	  the	  Mann-­‐Whitney	  test	  calculated	  the	  significance	  of	  differences	  between	  ACPA-­‐positive	  and	  ACPA-­‐negative	  patients	  with	  RA.	  The	  Spearman’s	  ranked	  correlation	  test	  calculated	  the	  significance	  of	  relationships	  between	  variables.	  In	  Study	  III,	  the	  student’s	  independent	  t-­‐test	  calculated	  the	  significance	  of	  differences	  between	  groups	  and	  the	  Pearson	  correlation	  coefficient,	  the	  significance	  of	  correlations	  between	  variables.	  In	  addition,	  linear	  multiple	  regression	  calculated	  the	  significance	  of	  relationships	  between	  the	  dependent	  variable	  of	  erosion	  score	  and	  the	  various	  independent	  variables.	  	  In	  Studies	  II	  and	  III,	  statistical	  analysis	  treated	  each	  TMJ	  in	  each	  patient	  as	  a	  separate	  entity	  to	  calculate	  the	  significance	  of	  relationships	  between	  variables	  related	  to	  a	  certain	  joint.	  On	  the	  other	  hand,	  we	  used	  the	  mean	  of	  both	  TMJs	  (right	  and	  left	  side)	  to	  calculate	  relationships	  between	  joint-­‐related	  and	  individual-­‐related	  variables.	  In	  the	  analyses,	  a	  probability	  level	  of	  less	  than	  0.05	  was	  considered	  significant.	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RESULTS	  AND	  DISCUSSION	  
Temporomandibular	  joint	  pain	  (Studies	  I	  and	  II)	  
Results	  Table	  2	  reports	  TMJ	  pain,	  the	  impact	  of	  this	  pain	  on	  daily	  living	  and	  quality	  of	  life,	  and	  serologic	  markers.	  	  Three	  patients	  (9%)	  reported	  no	  TMJ	  pain	  at	  all	  (during	  rest,	  mouth	  opening,	  or	  chewing)	  at	  the	  visit.	  Ten	  patients	  (32%)	  reported	  no	  TMJ	  pain	  at	  rest;	  six	  patients	  (19%)	  had	  no	  TMJ	  pain	  at	  maximum	  mouth	  opening,	  whereas	  eight	  patients	  (26%)	  had	  no	  TMJ	  pain	  while	  chewing.	  	   	  
Table&2
Median 25th 75th n Median 25th 75th n
TMJ)pain)intensity
At&rest 0"20 2 0 4 33 1 0 2 52
On&maximum&mouth&opening 0"20 9 5 11 33 8 5 14 26
On&chewing 0"20 4 2 8 33 2 0 4 52
Pain&on&movements 0"80 19 12 27 33 16 10 28 52
Tenderness)to)digital)palpation 0"8 4 2 4 33 2 1 3 52
Impact)of)TMJ)pain
On&daily&activity 0"10 3 2 5 33
Quality&of&life 0"10 3 2 5 33
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Patients	  with	  TMJ	  pain	  while	  chewing	  had	  a	  significantly	  higher	  DAS28	  and	  number	  of	  painful	  regions	  than	  patients	  without	  TMJ	  pain	  (p	  =	  0.036	  and	  p	  =	  0.022,	  respectively).	  	  Patients	  with	  pain	  at	  maximum	  mouth	  opening	  had	  a	  significantly	  higher	  DAS28	  than	  patients	  without	  pain	  at	  maximum	  mouth	  opening	  (p	  =	  0.037).	  
Discussion	  All	  participants	  had	  received	  a	  diagnosis	  of	  RA	  according	  to	  the	  1987	  American	  College	  of	  Rheumatology	  criteria	  and	  were	  all	  outpatients	  at	  one	  of	  the	  largest	  rheumatological	  clinics	  in	  Jeddah.	  Age,	  gender	  distribution,	  and	  prevalence	  of	  RF,	  ACPA,	  and	  serologic	  markers	  support	  the	  sample’s	  representativeness	  of	  the	  local	  RA	  community	  in	  Saudi	  Arabia	  and	  in	  the	  United	  Arab	  Emirates	  (121-­‐123).	  Patients	  had	  received	  their	  RA	  diagnosis	  at	  a	  mean	  age	  of	  41	  years,	  which	  corresponds	  well	  with	  many	  studies	  from	  various	  parts	  of	  the	  world	  (124).	  	  RA	  pain	  and	  systemic	  inflammatory	  activity,	  as	  assessed	  by	  the	  DAS28,	  are	  related	  (125).	  A	  high	  DAS28	  was	  associated	  with	  worse	  general	  pain	  and	  disability	  in	  early	  RA	  (125).	  In	  our	  studies,	  high	  systemic	  inflammatory	  activity,	  as	  assessed	  by	  the	  DAS28	  and	  number	  of	  painful	  regions,	  was	  associated	  with	  TMJ	  pain	  on	  function	  (mouth	  opening	  and	  chewing),	  indicating	  that	  systemic	  inflammatory	  activity	  is	  one	  determinant	  for	  TMJ	  pain.	  Indeed,	  various	  TMJ	  pain	  constructs	  (at	  rest,	  movement,	  loading,	  palpation,	  etc.)	  will	  modulate	  with	  the	  combination	  of	  local	  and	  systemic	  factors	  in	  RA.	  For	  example,	  TMJ	  pain	  on	  movement	  modulates	  mainly	  via	  local	  factors	  whereas	  the	  TMJ	  pressure	  pain	  threshold	  over	  the	  lateral	  pole	  modulates	  via	  systemic	  factors	  to	  a	  large	  extent	  (52).	  
Impact	  of	  temporomandibular	  joint	  pain	  and	  systemic	  
inflammatory	  activity	  on	  daily	  activities	  and	  quality	  of	  life	  	  
(Study	  I)	  
Results	  Four	  patients	  reported	  no	  restriction	  to	  activities	  of	  daily	  living	  due	  to	  TMJ	  pain.	  The	  TMJ	  pain	  variables	  –	  pain	  intensity	  in	  the	  TMJ	  at	  rest,	  at	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maximum	  mouth	  opening,	  and	  while	  chewing	  –	  showed	  significant	  impact	  on	  daily	  activities	  (rs	  =	  0.74,	  n	  =	  33,	  p	  <	  0.001;	  rs	  =	  0.72,	  n	  =	  33,	  p	  <	  0.001;	  and	  rs	  =	  0.72,	  n	  =	  33,	  p	  <	  0.001,	  respectively;	  Fig.	  5A	  and	  5B)	  and	  on	  quality	  of	  life	  (rs	  =	  0.70,	  n	  =	  33,	  p	  <	  0.001;	  rs	  =	  0.73,	  n	  =	  33,	  p	  <	  0.001;	  and	  rs	  =	  0.72,	  n	  =	  33,	  p	  <	  0.001,	  respectively;	  Fig.	  6A	  and	  6B).	  	  Total	  TMJ	  pain	  intensity	  during	  mandibular	  movements	  correlated	  with	  impact	  on	  daily	  activities	  and	  quality	  of	  life	  (rs	  =	  0.64,	  n	  =	  33,	  p	  <	  0.001	  and	  rs	  =	  0.63,	  n	  =	  33,	  p	  <	  0.001,	  respectively).	  Pain	  threshold	  correlated	  negatively	  with	  impact	  on	  daily	  activities	  and	  quality	  of	  life	  (rs	  =	  -­‐0.44,	  n	  =	  33,	  p	  <	  0.001	  and	  rs	  =	  -­‐0.43,	  n	  =	  33,	  p	  <	  0.001,	  respectively).	  The	  DAS28	  and	  number	  of	  painful	  regions	  correlated	  with	  the	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  (rs	  =	  0.43,	  n	  =	  32,	  p	  =	  0.014	  and	  rs	  =	  0.53,	  n	  =	  33,	  p	  =	  0.002,	  respectively)	  and	  on	  quality	  of	  life	  (rs	  =	  0.37,	  n	  =	  32,	  p	  =	  0.038	  and	  rs	  =	  0.49,	  n	  =	  33,	  p	  =	  0.004,	  respectively).	  The	  DAS28,	  in	  turn,	  was	  significantly	  related	  to	  the	  number	  of	  painful	  regions	  (rs	  =	  0.67,	  n	  =	  32,	  
p	  <	  0.001).	  Partial	  correlations,	  controlling	  for	  the	  influence	  of	  systemic	  inflammatory	  activity	  (DAS28),	  showed	  that	  the	  number	  of	  painful	  movements	  and	  number	  of	  painful	  regions	  still	  had	  a	  significant	  impact	  on	  daily	  activities,	  but	  to	  a	  lesser	  degree,	  (rs	  =	  0.58,	  n	  =	  29,	  p	  <	  0.001	  and	  rs	  =	  0.52,	  n	  =	  29,	  p	  =	  0.002,	  respectively)	  as	  did	  quality	  of	  life	  (rs	  =	  0.55,	  n	  =	  29,	  p	  <	  0.001	  and	  rs	  =	  0.54,	  n	  =	  29,	  p	  =	  0.002,	  respectively).	  	  Partial	  correlations,	  controlling	  for	  the	  influence	  of	  TMJ	  pain	  on	  movement	  (number	  of	  painful	  movements),	  showed	  that	  the	  number	  of	  painful	  regions,	  one	  measure	  of	  systemic	  inflammatory	  activity,	  had	  a	  significant	  impact	  on	  daily	  activities	  (rs	  =	  0.43,	  n	  =	  29,	  p	  =	  0.015)	  and	  quality	  of	  life	  (rs	  =	  0.42,	  n	  =	  29,	  p	  =	  0.020).	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Figure	  5.	  Scatter	  plots	  showing	  the	  relationship	  between	  temporomandibular	  joint	  
(TMJ)	  pain	  intensity	  during	  movement	  and	  the	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  
(A:	  rs	  =	  0.72,	  n	  =	  33,	  p	  <	  0.001)	  and	  quality	  of	  life	  (B:	  rs	  =	  0.73,	  n	  =	  33,	  p	  <	  0.001).	  
	  
	  
Figure	  6.	  Scatter	  plots	  showing	  the	  relationship	  between	  number	  of	  painful	  regions	  
and	  the	  impact	  of	  temporomandibular	  joint	  (TMJ)	  pain	  on	  daily	  activities	  (A:	  rs	  =	  0.53,	  
n	  =	  33,	  p	  =	  0.002)	  and	  quality	  of	  life	  (B:	  rs	  =	  0.49,	  n	  =	  33,	  p	  =	  0.004).	  
Discussion	  The	  main	  finding	  of	  Study	  I	  is	  that	  systemic	  inflammatory	  activity	  is	  an	  important	  factor	  behind	  the	  degree	  of	  impact	  of	  TMJ	  pain.	  The	  study	  also	  confirmed	  the	  substantial	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  and	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quality	  of	  life.	  This	  indicates	  that	  TMJ	  treatment	  planning	  and	  prognosis	  estimation	  for	  patients	  with	  RA	  should	  consider	  not	  only	  the	  intensity	  of	  TMJ	  pain	  but	  also	  systemic	  inflammatory	  activity.	  RA	  impacts	  many	  aspects	  of	  daily	  life	  due	  to	  pain,	  stiffness,	  and	  functional	  restrictions.	  The	  disorder	  is	  commonly	  accompanied	  by	  local	  joint	  pain	  that	  increases	  during	  movement	  and	  loading,	  which	  may	  severely	  affect	  and	  limit	  daily	  activities	  (112).	  Morning	  joint	  stiffness	  and	  pain	  are	  important	  features	  in	  RA	  (126).	  Such	  morning	  pain	  has	  a	  considerable	  impact	  on	  the	  daily	  living	  and	  well-­‐being	  of	  patients	  with	  RA	  (128).	  Indeed,	  in	  Study	  I,	  TMJ	  pain	  during	  movement	  and	  loading	  correlated	  with	  impact	  on	  daily	  activities	  and	  quality	  of	  life.	  These	  findings	  support	  previous	  studies	  in	  which	  TMJ	  pain	  seemed	  to	  have	  a	  substantial	  negative	  impact	  on	  activities	  of	  daily	  living	  in	  RA	  (91,	  111,	  127,	  128).	  Voog	  et	  al.	  (91)	  showed	  various	  levels	  of	  negative	  influence	  on	  activities	  of	  daily	  living	  in	  all	  included	  patients	  with	  RA.	  The	  impact	  on	  daily	  living	  of	  TMJ	  pain/discomfort	  in	  that	  study	  was	  greatest	  for	  physical	  exercises	  and	  jaw	  movements.	  Pain	  during	  maximum	  mouth	  opening	  was	  associated	  with	  difficulties	  in	  several	  activities,	  such	  as	  yawning	  and	  opening	  the	  mouth	  wide	  (72).	  TMJ	  movement	  pain	  is	  mainly	  related	  to	  local	  inflammatory	  activity	  (52).	  TMJ	  pain	  intensity	  during	  movement,	  together	  with	  the	  number	  of	  painful	  regions,	  was	  strongly	  associated	  with	  the	  degree	  of	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  and	  quality	  of	  life.	  This	  indicates	  that	  both	  local	  and	  systemic	  inflammatory	  activity	  are	  important	  and	  interrelated	  determinants	  for	  the	  consequences	  of	  the	  disease.	  	  The	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  and	  quality	  of	  life	  was	  higher	  in	  patients	  with	  high	  systemic	  inflammatory	  activity.	  In	  turn,	  higher	  systemic	  inflammatory	  activity	  was	  associated	  with	  TMJ	  pain	  during	  mouth	  opening	  and	  chewing.	  The	  present	  study	  investigated	  TMJ	  pain	  at	  rest	  and	  during	  movement	  and	  loading	  (chewing),	  as	  well	  as	  palpation	  pain.	  These	  variables	  represent	  pain	  constructs	  which,	  to	  some	  extent,	  represent	  a	  variety	  of	  peripheral	  pain	  mechanisms	  that	  may	  share	  similar	  central	  pain	  mechanisms.	  TMJ	  pain	  during	  movement	  and	  chewing	  represents	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mechanical	  sensitization	  in	  which	  normal	  use	  elicits	  pain,	  whereas	  palpation	  pain	  represents	  mechanical	  sensitization	  to	  externally	  applied	  pressure.	  In	  this	  context,	  pain	  at	  rest	  represents	  a	  mix	  of	  central	  and	  peripheral	  sensitization	  and	  activation	  of	  nociceptive	  mechanisms.	  However,	  the	  central	  mechanisms,	  in	  the	  trigeminal	  centers	  in	  the	  brain	  stem	  and	  other	  brain	  centers	  for	  affective	  and	  cognitive	  aspects	  of	  pain,	  for	  example,	  may	  also	  maintain	  chronic	  pain	  without	  a	  substantial	  sensory	  influx	  in	  the	  nociceptive	  system	  (129).	  This	  may	  amplify	  all	  pain	  aspects	  and	  may	  also	  contribute	  to	  TMJ	  pain.	  Our	  studies	  thus	  indicate	  that	  systemic	  inflammatory	  activity	  is	  a	  major	  factor	  behind	  the	  impact	  of	  TMJ	  pain	  on	  daily	  activities	  and	  quality	  of	  life.	  In	  the	  arthritic	  synovial	  membrane,	  immunoactive	  cells	  release	  inflammatory	  mediators	  like	  cytokines	  (TNF,	  IL-­‐1,	  IL-­‐6,	  etc.)	  to	  bind	  to	  local	  target	  receptors.	  These	  cytokines,	  which	  may	  also	  “spill	  over”	  into	  the	  blood	  and	  eventually	  reach	  the	  liver,	  have	  been	  shown	  to	  activate	  afferent	  portions	  of	  the	  vagus	  nerve	  passing	  through	  the	  liver,	  causing	  or	  modulating	  the	  “illness	  response”	  when	  the	  nerve	  signals	  reach	  the	  vagus	  centers	  in	  the	  brain.	  The	  illness	  response	  consists	  of	  fever,	  malaise,	  mood	  changes,	  reduced	  appetite	  and	  libido,	  fatigue,	  increased	  or	  disturbed	  sleep,	  and	  disturbed	  central	  pain	  modulation	  (130,	  131)	  and	  may	  therefore	  partly	  explain	  how	  TMJ	  inflammation	  influences	  central	  pain	  processing,	  in	  addition	  to	  peripheral	  sensitization	  of	  nociceptive	  nerve	  endings.	  Also,	  the	  cytokines	  found	  in	  blood	  increase	  the	  inflammatory	  markers	  of	  systemic	  inflammatory	  activity;	  thus,	  TMJ	  inflammation	  may	  influence	  systemic	  inflammatory	  activity	  and	  central	  pain	  processing	  via	  this	  mechanism.	  	  
Temporomandibular	  joint	  synovial	  fluid	  mediators	  	  
(Studies	  II	  and	  III)	  
Results	  Table	  3	  reports	  the	  investigated	  ratios	  between	  inflammatory	  mediators	  in	  the	  TMJ	  synovial	  fluid	  and	  the	  concentrations	  of	  TNF	  and	  IL-­‐1ra	  as	  well	  as	  their	  respective	  soluble	  receptor	  II	  in	  blood	  serum.	  In	  TMJ	  synovial	  
 30 
fluid,	  48%	  of	  the	  samples	  were	  ACPA	  positive.	  In	  ACPA-­‐positive	  TMJ	  synovial	  fluid,	  the	  ratio	  of	  TNF	  to	  IL-­‐1ra	  was	  significantly	  higher	  than	  in	  ACPA-­‐negative	  patients	  (p	  =	  0.001;	  Study	  III).	  Patients	  taking	  anti-­‐TNF	  medication	  had	  a	  significantly	  lower	  ratio	  between	  IL-­‐1ra	  and	  IL-­‐1sRII	  levels	  in	  TMJ	  synovial	  fluid	  than	  patients	  who	  were	  not	  (p	  =	  0.048).	  	  In	  TMJ	  synovial	  fluid,	  the	  ACPA	  level	  correlated	  significantly	  with	  TNF	  level	  (rs	  =	  0.47,	  n	  =	  52,	  p	  <	  0.001),	  CRP	  level	  (rs	  =	  0.60,	  n	  =	  52,	  p	  <	  0.001),	  and	  RF	  titer	  (rs	  =	  0.50,	  n	  =	  52,	  p	  <	  0.001),	  but	  not	  with	  TNFsRII	  level.	  This	  indicates	  that	  increased	  inflammatory	  activity	  depends	  in	  part	  on	  an	  insufficient	  increase	  in	  anti-­‐inflammatory	  mediators.	  The	  ratio	  between	  TNF	  and	  TNFsRII	  significantly	  correlated	  with	  ACPA	  level	  (rs	  =	  0.36,	  n	  =	  52,	  p	  =	  0.009),	  as	  well	  as	  CRP	  level	  (rs	  =	  0.47,	  n	  =	  52,	  p	  <	  0.001).	  	  	   	  Table&3
Median 25th 75th n Mean SD n
Ratios-between-TMJ-synovial-fluid-mediators
TNF/TNFsRII 0.6 0.5 0.7 52 0.7 0.4 44
TNF/CRP 15 11 26 52 21 15 44
TNF/RF 3.2 2.6 5.7 52 5.4 3.8 44
TNF/ACPA 8 4.4 12 52 9.1 5.1 44
IL>1ra/IL>1sRII 1.5 1.3 2.1 52 1.9 1.2 44
IL>1ra/TNF 2.1 1.7 2.5 52 2.2 1.2 44
Blood-serum-levels
TNF pg/mL 100 66 135 26 149 119 22
TNFsRII pg/mL 173 87 238 26 267 213 22
IL>1ra pg/mL 218 162 254 26 240 122 22
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Discussion	  Studies	  II	  and	  III	  show	  that	  excess	  levels	  of	  TNF	  in	  TMJ	  synovial	  fluid	  relative	  to	  its	  endogenous	  control,	  as	  assessed	  by	  TNFsRII,	  are	  associated	  with	  ongoing	  inflammatory	  activity.	  In	  Study	  II,	  high	  TMJ	  synovial	  fluid	  levels	  of	  ACPA,	  CRP,	  and	  RF	  correlated	  with	  excess	  levels	  of	  TNF,	  but	  not	  with	  the	  TNFsRII	  level.	  This	  means	  that	  insufficient	  cytokine	  control	  is	  probably	  an	  important	  factor	  behind	  increased	  inflammatory	  activity.	  	  Patients	  with	  ACPA-­‐positive	  TMJ	  synovial	  fluid	  also	  had	  higher	  TNF	  levels	  in	  their	  synovial	  fluid	  relative	  to	  IL-­‐1ra	  levels	  than	  did	  ACPA-­‐negative	  patients.	  In	  addition,	  high	  ACPA	  concentrations	  were	  associated	  with	  high	  TNF	  levels	  in	  TMJ	  synovial	  fluid.	  ACPA,	  the	  autoantibody	  for	  citrullinated	  peptides	  that	  is	  found,	  for	  example,	  in	  the	  synovial	  tissues,	  activates	  the	  immune	  system	  and	  would	  therefore	  be	  expected	  to	  contribute	  to	  TNF	  and	  IL-­‐1	  release.	  However,	  ACPA	  in	  synovial	  tissues	  seems	  to	  a	  larger	  extent	  to	  affect	  TNF	  production	  and	  release.	  	  Levels	  of	  ACPA	  in	  TMJ	  synovial	  fluid	  have	  never	  been	  reported	  before.	  In	  this	  study,	  48%	  of	  the	  TMJ	  synovial	  fluid	  samples	  were	  positive	  for	  ACPA.	  In	  the	  synovial	  fluid,	  ACPA	  levels	  were	  strongly	  related	  to	  levels	  of	  CRP	  and	  RF,	  supporting	  ACPA’s	  association	  with	  local	  inflammatory	  activity,	  as	  expected.	  In	  TMJ	  synovial	  fluid,	  high	  TNF	  was	  associated	  with	  a	  high	  level	  of	  TNFsRII.	  This	  indicates	  that	  inflammatory	  activity	  increases	  proinflammatory	  cytokines	  as	  well	  as	  their	  endogenous	  controls.	  However,	  since	  the	  soluble	  receptor	  level	  was	  not	  related	  to	  ACPA,	  CRP	  or	  RF	  in	  TMJ	  synovial	  fluid,	  the	  increase	  in	  the	  endogenous	  control	  is	  probably	  not	  always	  sufficient	  to	  control	  or	  inhibit	  the	  inflammatory	  process	  (132).	  	  
Systemic	  inflammatory	  activity	  (Studies	  I–III)	  
Results	  The	  percentage	  of	  patients	  who	  tested	  ACPA-­‐positive	  in	  serum	  was	  85%	  (Study	  II)	  and	  86%	  (Study	  III).	  In	  ACPA-­‐positive	  patients,	  significant	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correlations	  occurred	  between	  the	  concentrations	  of	  ACPA	  and	  TNF	  (rs	  =	  0.56,	  n	  =	  26,	  p	  =	  0.007;	  Study	  II)	  and	  TNFsRII	  (rs	  =	  0.51,	  n	  =	  26,	  p	  =	  0.016;	  Study	  III)	  in	  serum.	  In	  serum,	  TNF	  concentrations	  correlated	  with	  TNFsRII	  concentrations	  (rs	  =	  0.84,	  n	  =	  26,	  p	  <	  0.001;	  Study	  II).	  Also,	  ACPA-­‐positive	  patients	  had	  higher	  concentrations	  of	  IL-­‐1sRII	  in	  serum	  (p	  =	  0.004;	  Study	  II).	  	  
Discussion	  Presence	  of	  ACPA	  in	  blood	  correlates	  with	  higher	  systemic	  inflammatory	  activity	  and	  worse	  RA	  prognosis,	  in	  part	  perhaps	  due	  to	  a	  consistent	  stimulation	  of	  TNF	  production	  and	  release	  (133,	  134).	  In	  our	  studies,	  84–85%	  of	  the	  patients	  had	  ACPA	  in	  their	  blood,	  compared	  to	  approximately	  72%	  in	  samples	  from	  Western	  European	  countries	  (135).	  However,	  in	  a	  study	  on	  Egyptian	  patients	  with	  RA,	  the	  proportion	  of	  ACPA-­‐positive	  patients	  was	  found	  to	  be	  84%	  (136),	  which	  is	  similar	  to	  what	  we	  found	  in	  this	  study	  of	  a	  similar	  RA	  population.	  	  High	  ACPA	  levels	  were	  associated	  with	  high	  TNF	  levels	  in	  TMJ	  synovial	  fluid.	  ACPA,	  that	  is,	  the	  autoantibody	  towards	  citrullinated	  peptides	  found,	  for	  example,	  in	  the	  synovial	  tissues,	  activates	  the	  immune	  system	  and	  can	  therefore	  be	  expected	  to	  contribute	  to	  TNF	  release.	  ACPA	  levels	  in	  TMJ	  synovial	  fluid	  have	  never	  been	  reported	  before.	  Presence	  of	  ACPA	  in	  blood	  indicates	  higher	  inflammatory	  activity	  and	  a	  worse	  prognosis,	  in	  part	  possibly	  due	  to	  elevated	  TNF	  levels	  (133,	  134).	  	  
Modulation	  of	  temporomandibular	  joint	  pain	  (Study	  II)	  
Results	  There	  was	  a	  positive	  correlation	  between	  high	  levels	  of	  TNF	  compared	  to	  TNFsRII	  in	  TMJ	  synovial	  fluid	  and	  pain	  during	  posterior	  palpation	  of	  the	  TMJ	  at	  maximum	  mouth	  opening	  (rs	  =	  0.32,	  n	  =	  52,	  p	  =	  0.022).	  	  High	  levels	  of	  IL-­‐1ra	  compared	  to	  IL-­‐1sRII	  in	  TMJ	  synovial	  fluid	  positively	  correlated	  with	  palpation	  pain	  of	  the	  lateral	  TMJ	  pole,	  as	  well	  as	  with	  total	  tenderness	  to	  TMJ	  palpation	  (rs	  =	  0.31,	  n	  =	  52,	  p	  =	  0.025	  and	  rs	  =	  0.31,	  n	  =	  52,	  p	  =	  0.024,	  respectively;	  Fig.	  7).	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Discussion	  Study	  II	  shows	  that	  TMJ	  palpation	  pain	  in	  RA	  is	  related	  to	  high	  TNF	  and	  IL-­‐1ra	  levels	  relative	  to	  their	  soluble	  anti-­‐inflammatory	  receptors	  TNFsRII	  and	  IL-­‐1sRII	  in	  TMJ	  synovial	  fluid.	  High	  levels	  of	  ACPA,	  CRP,	  and	  RF	  in	  TMJ	  synovial	  fluid	  correlate	  with	  increased	  concentrations	  of	  TNF,	  but	  not	  of	  TNFsRII.	  A	  deficiency	  in	  local	  cytokine	  control	  thus	  seems	  to	  contribute	  to	  inflammatory	  activity,	  including	  decreased	  mechanical	  pain	  thresholds	  in	  the	  TMJ.	  	  A	  relative	  excess	  of	  the	  proinflammatory	  cytokines	  TNF	  and	  IL-­‐1	  in	  the	  TMJ	  synovial	  fluid	  relative	  to	  their	  endogenous	  control,	  as	  assessed	  by	  TNFsRII	  and	  IL-­‐1sRII,	  thus	  seems	  to	  sensitize	  the	  articular	  and/or	  adjacent	  tissues	  to	  mechanical	  stimulation.	  However,	  from	  the	  results	  of	  this	  study	  it	  is	  unclear	  if	  this	  sensitization	  is	  local/peripheral	  or	  systemic/central	  in	  origin,	  or	  if	  it	  is	  a	  combination.	  TMJ	  pain	  to	  palpation	  has	  shown	  to	  be	  due	  to	  either	  local/peripheral	  sensitization	  to	  mechanical	  stimuli	  of	  the	  articular	  tissues	  or	  the	  tissues	  overlying	  the	  TMJ,	  systemic/central	  sensitization,	  or	  both	  (47).	  There	  is	  at	  least	  15	  mm	  from	  the	  surface	  of	  the	  skin	  to	  the	  most	  lateral	  part	  of	  the	  TMJ	  capsule	  and	  lateral	  pole	  (Holmlund,	  personal	  communication).	  Palpation	  over	  the	  lateral	  pole	  of	  the	  TMJ	  thus	  also	  affects	  tissues	  other	  than	  the	  joint,	  such	  as	  muscles,	  skin,	  subcutaneous	  tissue,	  and	  connective	  tissue.	  These	  tissues	  may	  well	  be	  systemically	  or	  centrally	  sensitized	  and	  pain	  on	  palpation	  may	  therefore	  reflect	  more	  of	  a	  systemically	  mediated	  sensitization.	  Indeed,	  Alstergren	  et	  al.	  found	  that	  the	  pressure	  pain	  threshold	  over	  the	  TMJ	  in	  systemic	  joint	  diseases	  involving	  the	  TMJ,	  that	  is,	  mechanical	  stimulation	  in	  the	  same	  manner	  as	  digital	  palpation,	  is	  related	  only	  to	  systemic	  factors	  and	  not	  to	  local	  (intra-­‐articular)	  inflammatory	  mediators	  (52).	  The	  correlation	  found	  in	  the	  present	  study	  between	  pain	  on	  palpation	  and	  a	  disturbed	  intra-­‐articular	  ratio	  between	  TNF	  and	  one	  of	  its	  soluble	  receptors	  might	  therefore	  include	  the	  influence	  of	  central	  sensitization	  to	  a	  substantial	  degree.	  	  A	  deficiency	  in	  cytokine	  control	  mechanisms	  (soluble	  receptors,	  decoy	  receptors,	  anti-­‐inflammatory	  cytokines,	  etc.)	  seems	  to	  associate	  with	  increased	  articular	  pain	  as	  well	  as	  tissue	  degradation	  (137).	  Low	  plasma	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levels	  of	  TNFsRII,	  indicating	  compromised	  endogenous	  cytokine	  control,	  seem	  strongly	  related	  to	  both	  TMJ	  pain	  and	  tissue	  destruction	  (55).	  	  
	   	  
Figure	   7.	   Scatter	   plot	   showing	   the	   relation	   of	  
interleukin	   I	   receptor	   antagonist	   (IL-­‐1ra)	   to	  
soluble	   interleukin	   I	   receptor	   type	   II	   (IL-­‐1sRII)	  
levels	   in	   the	   temporomandibular	   joint	   (TMJ)	  
synovial	   fluid	   of	   26	   patients	   with	   rheumatoid	  
arthritis	   compared	   to	   TMJ	   pain	   on	   palpation	  
(rs	  =	  0.31,	  n	  =	  52,	  p	  =	  0.025).	  
	  
Temporomandibular	  joint	  erosions	  (Study	  III)	  
Results	  	  The	  majority	  of	  TMJ	  erosions	  occurred	  on	  the	  condyle.	  Of	  the	  132	  TMJ	  condyle	  regions	  examined,	  38%	  had	  erosions,	  compared	  to	  only	  3%	  in	  the	  temporal	  areas	  (p	  =	  0.001).	  Of	  these	  erosions,	  24%	  occurred	  in	  the	  medial	  regions	  of	  the	  condyle,	  29%	  in	  the	  lateral	  regions,	  and	  the	  majority,	  53%,	  in	  the	  central	  regions	  of	  the	  condyle.	  The	  total	  erosion	  scores	  of	  the	  condyle	  and	  of	  the	  temporal	  portion	  correlated	  with	  each	  other	  (rs	  =	  0.65,	  n	  =	  44,	  p	  <	  0.001).	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Discussion	  Erosions	  were	  only	  occasionally	  observed	  in	  the	  temporal	  portion	  of	  the	  TMJ,	  but	  these	  correlated	  with	  erosive	  changes	  on	  the	  condyle.	  Several	  previous	  studies	  that	  used	  MRI	  and	  CT	  to	  assess	  erosive	  changes	  support	  these	  findings	  (50,	  71,	  138).	  A	  previous	  study	  shows	  that	  most	  radiographic	  changes	  occurred	  in	  the	  condylar	  region	  with	  far	  fewer	  in	  the	  temporal	  part	  (118).	  The	  study	  concluded	  that	  radiographic	  changes	  were	  primarily	  located	  on	  the	  condyle.	  	  Another	  study	  showed	  (139)	  that	  systemic	  inflammatory	  activity,	  as	  assessed	  by	  DAS28	  and	  CRP,	  was	  strongly	  related	  to	  MR	  bone	  tissue	  erosion	  in	  wrist/metacarpophalangeal	  joints.	  Also,	  that	  study	  confirmed	  that	  changes	  in	  CRP	  are	  related	  to	  changes	  in	  MR	  measures	  of	  inflammation,	  like	  synovitis	  and	  edema.	  Changes	  in	  the	  DAS28	  score	  did	  not	  relate	  strongly	  with	  changes	  in	  the	  MR	  scores,	  probably	  because	  of	  the	  composite	  nature	  of	  the	  DAS28,	  which	  includes	  a	  tender	  joint	  count	  and	  pain	  intensity	  not	  assessed	  by	  MR.	  	  
Temporomandibular	  joint	  erosions	  in	  relation	  to	  synovial	  fluid	  
mediators	  (Study	  III)	  
Results	  High	  levels	  of	  TNF	  relative	  to	  TNFsRII	  in	  the	  TMJ	  synovial	  fluid	  correlated	  with	  the	  TMJ	  condylar	  erosion	  score	  (rs	  =	  0.32,	  n	  =	  44,	  p	  =	  0.036;	  Fig.	  2	  in	  Study	  III).	  	  The	  erosion	  scores	  of	  the	  medial	  condylar	  region	  and	  the	  posterior	  temporal	  area	  each	  correlated	  with	  TNF/TNFsRII	  ratios	  in	  the	  TMJ	  synovial	  fluid	  (rs	  =	  0.31,	  n	  =	  44,	  p	  =	  0.042	  and	  rs	  =	  0.40,	  n	  =	  44,	  p	  =	  0.007).	  Multiple	  regression	  revealed	  no	  significant	  contribution	  of	  the	  independent	  relations	  TNF/TNFsRII	  or	  IL-­‐1ra/IL-­‐1sRII	  versus	  the	  dependent	  variable	  erosion	  score.	  	  
Discussion	  Study	  III	  shows	  that	  a	  relative	  excess	  levels	  of	  TNF	  in	  the	  TMJ	  synovial	  fluid	  compared	  to	  its	  endogenous	  control,	  as	  assessed	  by	  TNFsRII,	  are	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associated	  with	  ongoing	  inflammatory	  activity,	  resulting	  in	  TMJ	  bone	  tissue	  resorption.	  Our	  findings	  further	  indicate	  that	  changes	  in	  the	  temporal	  portion	  occur	  in	  TMJs	  with	  more	  severe	  inflammatory	  activity	  involving	  bone	  tissue	  changes.	  High	  TMJ	  synovial	  fluid	  levels	  of	  TNF	  relative	  to	  TNFsRII	  were	  associated	  with	  erosive	  changes	  of	  the	  TMJ	  cartilage	  and	  bone	  tissue.	  TNF	  plays	  a	  major	  role	  in	  RA,	  not	  least	  by	  promoting	  cartilage	  and	  bone	  tissue	  destruction	  (50).	  The	  cytokine	  stimulates	  the	  release	  of	  matrix	  metalloproteinases	  and	  other	  proteolytic	  enzymes	  that	  degrade	  proteoglycans.	  TNF	  also	  has	  potent	  effects	  on	  bone	  metabolism	  by	  stimulating	  osteoclast	  formation	  and	  activity	  while	  inhibiting	  osteoblast	  formation	  of	  new	  bone	  tissue.	  Our	  findings	  also	  indicate	  that	  the	  relationship	  between	  these	  pro-­‐	  and	  anti-­‐inflammatory	  factors	  to	  some	  extent	  determines	  local	  inflammatory	  activity,	  including	  TMJ	  bone	  tissue	  resorption.	  Insufficient	  endogenous	  control	  of	  TNF,	  as	  represented	  by	  low	  TMJ	  synovial	  fluid	  levels	  of	  TNFsRII	  relative	  to	  TNF,	  may	  therefore	  be	  a	  risk	  factor	  for	  developing	  structural	  TMJ	  changes.	  This	  has	  been	  reported	  before	  in	  cases	  where	  insufficient	  systemic	  endogenous	  control	  of	  TNF	  was	  found	  to	  contribute	  to	  TMJ	  pain	  and	  tissue	  destruction	  in	  RA	  (140).	  Study	  II	  found	  that	  deficient	  TNF	  control	  by	  TNFsRII	  was	  related	  to	  TMJ	  pain	  in	  RA.	  Insufficient	  formation	  of	  soluble	  TNF	  receptors	  may	  thus	  contribute	  to	  the	  development	  or	  maintenance	  of	  inflammation	  (141).	  It	  was,	  however,	  not	  possible	  in	  the	  present	  studies	  to	  determine	  which	  factor,	  a	  high	  TNF	  or	  a	  low	  TNFsRII	  level,	  was	  the	  most	  important	  for	  TMJ	  bone	  tissue	  resorption.	  	  	  TNF	  and	  ACPA	  have	  been	  separately	  associated	  with	  structural	  joint	  damage	  (142).	  Patients	  who	  were	  positive	  for	  ACPA	  in	  the	  TMJ	  synovial	  fluid	  had	  higher	  TNF	  synovial	  fluid	  levels	  in	  the	  TMJ	  relative	  to	  IL-­‐1ra	  levels	  than	  did	  ACPA-­‐negative	  patients.	  This	  suggests	  that	  presence	  of	  ACPA	  in	  synovial	  tissues	  has	  a	  strong	  affect	  on	  TNF	  production	  and	  release.	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Temporomandibular	  joint	  erosions	  in	  relation	  to	  systemic	  
inflammatory	  activity	  (Study	  III)	  
Results	  The	  total	  (right	  +	  left)	  score	  of	  TMJ	  condylar	  erosion,	  as	  well	  as	  the	  total	  score	  of	  TMJ	  temporal	  erosions,	  correlated	  with	  number	  of	  painful	  regions	  (rs	  =	  0.61,	  n	  =	  22,	  p	  =	  0.003	  and	  rs	  =	  0.56,	  n	  =	  22,	  p	  =	  0.007).	  Number	  of	  painful	  regions	  also	  correlated	  with	  the	  DAS28	  (rs	  =	  0.63,	  n	  =	  22,	  p	  =	  0.001).	  Patients	  taking	  anti-­‐TNF	  medication	  had	  significantly	  lower	  IL-­‐1ra	  relative	  to	  IL-­‐1sRII	  levels	  in	  TMJ	  synovial	  fluid	  than	  patients	  who	  were	  not	  (p	  =	  0.048).	  	  
Discussion	  ACPA	  positivity	  in	  the	  blood	  may	  provide	  an	  early	  means	  of	  differentiating	  between	  patients	  with	  erosive	  and	  non-­‐erosive	  RA	  (134).	  ACPA	  positivity	  in	  the	  blood	  is	  associated	  with	  progressive	  radiographic	  joint	  destruction	  in	  patients	  with	  recent-­‐onset	  RA	  (143).	  Presence	  of	  ACPA	  in	  the	  blood	  also	  indicates	  higher	  inflammatory	  activity,	  in	  part	  perhaps	  due	  to	  elevated	  TNF	  levels	  (133,	  134).	  	  ACPA	  can	  induce	  differentiation	  of	  bone-­‐resorbing	  osteoclasts	  from	  monocytic	  precursors	  and	  activate	  osteoclasts,	  thereby	  contributing	  to	  bone	  tissue	  loss	  (144).	  Bone	  tissue	  damage	  in	  early	  and	  even	  recent-­‐onset	  RA,	  which	  occurs	  years	  before	  arthritis	  starts	  and	  clinical	  symptoms	  begin	  to	  emerge,	  has	  been	  attributed	  to	  ACPA	  (145).	  ACPA	  is	  associated	  with	  bone	  tissue	  loss	  and	  alterations	  in	  bone	  tissue	  metabolism	  before	  the	  clinical	  onset	  of	  arthritis,	  suggesting	  that	  these	  antibodies	  are	  linked	  to	  structural	  bone	  damage	  in	  RA	  (144).	  	  Patients	  on	  anti-­‐TNF	  medication	  had	  lower	  IL-­‐1ra	  levels	  relative	  to	  IL-­‐1sRII	  in	  TMJ	  synovial	  fluid.	  Although	  this	  study	  detected	  no	  significant	  relationship	  between	  IL-­‐1ra	  or	  IL-­‐1sRII	  and	  bone	  tissue	  changes	  in	  the	  TMJ,	  this	  finding	  indicates	  that	  anti-­‐TNF	  medication	  influences	  the	  cytokine	  balance	  for	  cytokines	  other	  than	  TNF.	  This	  was	  expected,	  however,	  and	  has	  been	  shown	  before	  (146).	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CONCLUSIONS	  	  TMJ	  pain	  intensity	  and	  systemic	  inflammatory	  activity	  in	  patients	  with	  RA	  are	  involved	  in	  activities	  of	  daily	  living	  and	  quality	  of	  life	  impairment.	  	  	  TMJ	  pain	  in	  RA	  seems	  to	  be	  related	  to	  a	  deficiency	  in	  local	  cytokine	  control	  that	  contributes	  to	  increased	  inflammatory	  activity,	  including	  lowered	  mechanical	  pain	  thresholds	  over	  the	  TMJ.	  	  TNF	  in	  TMJ	  synovial	  fluid	  seems	  to	  be	  one	  factor	  mediating	  TMJ	  bone	  tissue	  resorption	  in	  RA.	  The	  degree	  of	  endogenous	  TNF	  control	  seems	  to	  contribute	  to	  TMJ	  bone	  tissue	  destruction.	  	  In	  summary,	  TNF,	  including	  its	  endogenous	  control	  system,	  seems	  to	  be	  involved	  in	  TMJ	  inflammation,	  which	  results	  in	  TMJ	  pain	  and	  tissue	  destruction.	  In	  turn,	  TMJ	  pain	  has	  a	  negative	  impact	  on	  daily	  living	  and	  quality	  of	  life	  in	  patients	  with	  RA.	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